EP4601644A1 - Méthodes de traitement de cancers à l'aide de dérivés d'isoquinoline ou de 6-aza-quinoléine - Google Patents

Méthodes de traitement de cancers à l'aide de dérivés d'isoquinoline ou de 6-aza-quinoléine

Info

Publication number
EP4601644A1
EP4601644A1 EP23805790.5A EP23805790A EP4601644A1 EP 4601644 A1 EP4601644 A1 EP 4601644A1 EP 23805790 A EP23805790 A EP 23805790A EP 4601644 A1 EP4601644 A1 EP 4601644A1
Authority
EP
European Patent Office
Prior art keywords
cancer
compound
alkyl
inhibitors
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23805790.5A
Other languages
German (de)
English (en)
Inventor
Yoon-Chi Han
Tai-An Lin
Luisa SHIN OGAWA
Anthony F. TROMBINO
Agata Jurczyk
Pui Yee Ng
Sergey YURASOV
Sudharshan Eathiraj
Julio José HAJDENBERG
David M. Epstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Black Diamond Therapeutics Inc
Original Assignee
Black Diamond Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black Diamond Therapeutics Inc filed Critical Black Diamond Therapeutics Inc
Publication of EP4601644A1 publication Critical patent/EP4601644A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present disclosure provides a compound of the present disclosure for treating or preventing cancer in a subject.
  • the present disclosure provides a use of a compound of the present disclosure in the manufacture of a medicament for treating cancer in a subject.
  • the present disclosure provides a combination comprising a compound of the present disclosure and one or more additional therapeutic agents, for treating cancer in a subject.
  • the present disclosure provides a use of a combination comprising a compound of the present disclosure and one or more additional therapeutic agents, in the manufacture of a medicament for treating or preventing cancer in a subject.
  • the present disclosure provides a compound of the present disclosure for use in combination with one or more additional therapeutic agents in treating cancer in a subject.
  • the present disclosure provides a use of a combination comprising a compound of the present disclosure and one or more additional therapeutic agents, in the manufacture of a medicament for treating or preventing cancer in a subject.
  • the present disclosure provides a use of a combination comprising a compound of the present disclosure and one or more additional therapeutic agents, in the manufacture of a medicament for treating cancer in a subject.
  • FIG. 3 is a graph depicting the anti-tumor activity of a compound of the present disclosure (the “Compound”) in combination with binimetinib in mice with melanoma cell line with BRAF V600E mutation.
  • RTKs receptor tyrosine kinases
  • RAS-GTP activates a Mitogen Activated Protein kinase kinase kinase (MAPKKK or MAP3K).
  • MAPKKK Mitogen Activated Protein kinase kinase kinase
  • MAPKK MAP kinase kinase
  • MAPK MAP kinase
  • MAPK MAP kinase
  • MAPK MAP kinase
  • MAPK MAP kinase
  • Activated MAPK then activates downstream effectors, including transcriptions factors, causing changes in gene expression, thereby regulating the various cellular processes described above, including, but not limited to, cellular growth, proliferation, differentiation and apoptosis.
  • BRAF mutations are typically categorized into one of three classes based on the mutations effect on B-Raf activity.
  • BRAF B-Raf proteins that are RAS-independent, active monomers. These RAS-independent, active monomers typically demonstrate elevated levels of kinase activity.
  • Class II (or Class 2) mutations are mutations that result in the expression of mutant B- Raf that can form active dimers independent of RAS. That is, Class II mutations in BRAF yield the expression of B-Raf proteins that are RAS-independent, active dimers. These RAS- independent, active dimers also display intermediate to high levels of kinase activity, but their activity levels are typically lower compared to the RAS-independent, active monomers produced by Class I BRAF mutations.
  • Class III or Class 3 mutations are mutations that result in the expression of mutant B- Raf that are RAS dependent (i.e. must be activated by RAS-GTP) and that can form heterodimers with other MAPK proteins such as C-Raf. Class III mutations in BRAF typically yield B-Raf with low or impaired kinase activity.
  • BRAF mutations are RAS-independent, the mutant B-Raf proteins harboring Class I or Class II mutations are uncoupled to any upstream signals, resulting in constitutive activation that can result in unchecked cellular growth and eventually oncogenic proliferation.
  • the present disclosure provides a method of treating or preventing cancer in a subject, the method comprising administering to the subject a compound of the present disclosure (e.g., in a therapeutically effective amount).
  • the present disclosure provides a method of treating cancer in a subject, the method comprising administering to the subject a compound of the present disclosure (e.g., in a therapeutically effective amount).
  • the present disclosure provides a use of a compound of the present disclosure in the manufacture of a medicament for treating or preventing cancer in a subject.
  • the present disclosure provides a use of a compound of the present disclosure in the manufacture of a medicament for treating cancer in a subject.
  • one or more inhibitors of one or more component of the MAPK pathways are further administered to the subject.
  • the subject is a mammal.
  • the subject is a human.
  • the subject is a rat.
  • the subject is a dog.
  • the subject is a monkey.
  • a cancer that is characterized by at least one oncogenic mutation in the BRAF gene is a cancer that is typically associated with at least one oncogenic mutation in the BRAF gene, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic mutation in the BRAF gene.
  • the cancer is characterized by at least one oncogenic variant of B-Raf.
  • a cancer that is characterized by least one oncogenic variant of B- Raf is a cancer that is typically associated with at least one oncogenic variant of B-Raf, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic variant of B-Raf.
  • an oncogenic variant of B-Raf is a B-Raf protein that comprises at least one oncogenic mutation and that is produced as the result of the expression of a BRAF gene that comprises at least one oncogenic mutation.
  • the subject has at least one oncogenic mutation in the BRAF gene.
  • the subject has at least one tumor and/or cancerous cell that expresses an oncogenic variant of B-Raf.
  • a gene e.g.
  • an oncogenic mutation can include, but is not limited to a mutation that results in the substitution of one amino acid for another at a specific position within B-Raf, a mutation that results in the substitution of one or more amino acids for one or more amino acids between two specific positions within B-Raf, a mutation that results in an insertion of one or more amino acids between two positions within B-Raf, a mutation that results in the deletion of one more amino acids between two positions within B-Raf, and mutation that results in a fusion of B-Raf, or portion thereof, with another protein, or portion thereof, or any combination thereof.
  • an oncogenic mutation can include, but is not limited to, the substitution of one amino acid for another at a specific position within B-Raf, the substitution of one or more amino acids for one or more amino acids between two specific positions within B-Raf, an insertion of one or more amino acids between two positions within B-Raf, a deletion of one more amino acids between two positions within B-Raf, and a fusion of B-Raf, or portion thereof, with another protein, or portion thereof, or any combination thereof.
  • the protein in the context of a protein (e.g. B-Raf), the protein can have one or more of the aforementioned types of oncogenic mutations, including combinations of different types of oncogenic mutations.
  • an oncogenic mutation of B-Raf can be any of the B-Raf mutations put forth in Table la.
  • An oncogenic variant of B-Raf can comprise one or more than one of the oncogenic mutations put forth in Table la in any combination.
  • an oncogenic variant of B-Raf can comprise the oncogenic mutations K601E and S363F.
  • L485-P490>Y and L485-P490Y refers to the substitution residues L485 through P490 of B-Raf (SEQ ID NO: 1) with a Tyrosine (Y) residue.
  • an oncogenic mutation of B-Raf can comprise a deletion of any combination of one or more amino acids between L485 and P490 of B-Raf (SEQ ID NO: 1). In some embodiments, an oncogenic mutation of B-Raf can comprise a deletion of any combination of one or more amino acids between L485 and Q494 of B-Raf (SEQ ID NO: 1). In some embodiments, an oncogenic mutation of B-Raf can comprise a deletion of any combination of one or more amino acids between A481 and Q494 of B-Raf (SEQ ID NO: 1).
  • an oncogenic mutation of B-Raf can comprise a deletion of any combination of one or more amino acids between K475 and N500 of B-Raf (SEQ ID NO: 1). In some embodiments, any of the preceding deletions can further comprise any combination of one or more substitutions and/or insertions within the range of residues indicated.
  • a wild type B-Raf sequence of the present disclosure may comprise, consist essentially of, or consist of the amino acid sequence of:
  • the oncogenic mutation is a class I mutation. Accordingly, in some embodiments, the oncogenic variant of B-Raf comprises a class I mutation.
  • the oncogenic mutation is a class II mutation. Accordingly, in some embodiments, the oncogenic variant of B-Raf comprises a class II mutation.
  • the oncogenic mutation is a class III mutation. Accordingly, in some embodiments, the oncogenic variant of B-Raf comprises a class III mutation.
  • the oncogenic variant of B-Raf can be any of the B-Raf variants put forth in Table lb. Any of the variants put forth in Table lb can be combined with any of the other variants put forth in Table lb.
  • an oncogenic variant of B-Raf can be B-Raf-K601E+S363F.
  • an oncogenic variant of B-Raf can comprise a deletion of any combination of one or more amino acids between K475 and N500 of B-Raf (SEQ ID NO: 1). In some embodiments, any of the preceding deletions can further comprise any combination of one or more substitutions and/or insertions within the range of residues indicated.
  • B-Raf-exl0-18dup refers to an oncogenic variant of B-Raf that comprises a duplication of exons 10 through 18 (see e.g. Kemper et al. Cell Rep. 2016 Jun 28; 16(1): 263-277, incorporated by reference herein for all purposes).
  • the oncogenic B-Raf-exl0-18dup can emerge after treatment with a BRAF inhibitor and/or MEK inhibitor.
  • the B-Raf-exl0-18dup can mediate resistance to the BRAF inhibitor and/or MEK inhibitor.
  • a subject has at least one tumor and/or cancerous cell that expresses an oncogenic variant of B-Raf and at least one additional protein in the RAF and/or MAPKZERK signaling pathways that comprises at least one mutation.
  • the at least one additional protein can be selected from N-Ras, K-Ras, Neurofibromin 1 (NF1).
  • the at least one mutation in the at least one additional protein can be an oncogenic mutation.
  • a subject has at least one tumor and/or cancerous cell that expresses an oncogenic variant of B-Raf and an N-Ras protein comprising at least one mutation.
  • an N-Ras protein comprising at least one mutation can be N-Ras-G12D, N-Ras-Q61K, and/or N-Ras-Q61R.
  • an N-Ras protein comprising at least one mutation can be N-Ras-Q61L and/or N-Ras-G13D.
  • a subject can have at least one tumor and/or cancerous cell that expresses B-Raf- D594G and N-Ras-G12D.
  • a subject has at least one tumor and/or cancerous cell that expresses an oncogenic variant of B-Raf and a K-Ras protein comprising at least one mutation.
  • a K-Ras protein comprising at least one mutation can be K-Ras-G12V, K-Ras-G12D, K-Ras-G12A, K-Ras-G12S, K-Ras-G12C, K-Ras-Q61H, K-Ras-Q61L, K-Ras- G13C and/or K-Ras-G13D.
  • a subject has at least one tumor and/or cancerous cell that expresses an oncogenic variant of B-Raf and an NF1 protein comprising at least one mutation.
  • NF1 proteins include, but are not limited to missense mutations, nonsense mutations, frameshift mutations, and splice site mutations, insertions, deletions, and translocations.
  • the cancer is characterized by at least one oncogenic mutation in at least one protein in the RAF and/or MAPKZERK signaling pathways.
  • the at least one protein in the RAF and/or MAPKZERK signaling pathways can be selected from N-Ras, K-Ras, and NF 1.
  • the cancer is characterized by at least one oncogenic mutation in the KRAS gene.
  • a cancer that is characterized by at least one oncogenic mutation in the KRAS gene is a cancer that is typically associated with at least one oncogenic mutation in the KRAS gene, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic mutation in the KRAS gene.
  • an oncogenic mutation in the KRAS gene induces the formation of one or more homodimers and/or heterodimers of Raf proteins.
  • an oncogenic mutation in the KRAS gene can induce the formation of A-Raf homodimers.
  • an oncogenic mutation in the KRAS gene can induce the formation of B-Raf homodimers.
  • an oncogenic mutation in the KRAS gene can induce the formation of C-Raf homodimers.
  • an oncogenic mutation in the KRAS gene can induce the formation of B-Raf/C-Raf heterodimers, A-Raf/B-Raf heterodimers, and/or A-Raf/C-Raf heterodimers.
  • the cancer is characterized by at least one oncogenic variant of K-Ras.
  • an oncogenic variant of K-Ras induces the formation of one or more homodimers and/or heterodimers of Raf proteins.
  • the at least one oncogenic variant of K-Ras can induce the formation of A-Raf homodimers.
  • the at least one oncogenic variant of K-Ras can induce the formation of B- Raf homodimers.
  • the at least one oncogenic variant of K-Ras can induce the formation of C-Raf homodimers.
  • the at least one oncogenic variant of K-Ras can induce the formation of B-Raf/C-Raf heterodimers, A-Raf/B- Raf heterodimers, and/or A-Raf/C-Raf heterodimers.
  • a cancer that is characterized by least one oncogenic variant of K- Ras is a cancer that is typically associated with at least one oncogenic variant of K-Ras, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic variant of K-Ras.
  • an oncogenic variant of K-Ras is a K-Ras protein that comprises at least one oncogenic mutation and that is produced as the result of the expression of a.
  • KRAS gene that comprises at least one oncogenic mutation.
  • the subject has at least one oncogenic mutation in the KRAS gene.
  • the subject has at least one tumor and/or cancerous cell that expresses an oncogenic variant of K-Ras.
  • an oncogenic mutation of K-Ras can be selected from K-Ras- G12V, K-Ras-G12D, K-Ras-G12A, K-Ras-G12S, K-Ras-G12C, K-Ras-Q61H, K-Ras-Q61L, K-Ras-G13C and K-Ras-G13D.
  • an oncogenic mutation of K-Ras can be a mutation that induces constitutive RAF dimer activation.
  • an oncogenic mutation of K-Ras is a mutation that is not K-Ras-G12C.
  • an oncogenic mutation of K-Ras can be K-Ras-G12D.
  • an oncogenic mutation of K-ras can be K-Ras-G12V.
  • the subject has at least one oncogenic mutation in the KRAS gene, wherein the at least one oncogenic mutation in the KRAS gene induces the formation of one or more homodimers and/or heterodimers of Raf proteins.
  • the at least one oncogenic mutation in the KRAS gene can induce the formation of A-Raf homodimers.
  • the at least one oncogenic mutation in the KRAS gene can induce the formation of B-Raf homodimers.
  • the at least one oncogenic mutation in the KRAS gene can induce the formation of C-Raf homodimers.
  • the at least one oncogenic mutation in the KRAS gene can induce the formation of B-Raf/C-Raf heterodimers, A-Raf/B-Raf heterodimers, and/or A-Raf/C-Raf heterodimers.
  • the subject has at least one tumor and/or cancerous cell that expresses an oncogenic variant of K-Ras, wherein oncogenic variant of K-Ras induces the formation of one or more homodimers and/or heterodimers of Raf proteins.
  • the oncogenic variant of K-Ras can induce the formation of A-Raf homodimers.
  • the oncogenic variant of K-Ras can induce the formation of B-Raf homodimers.
  • the oncogenic variant of K-Ras can induce the formation of C-Raf homodimers.
  • the a oncogenic variant of K-Ras can induce the formation of B-Raf/C-Raf heterodimers, A-Raf/B-Raf heterodimers, and/or A- Raf/C-Raf heterodimers.
  • the cancer is characterized by at least one oncogenic mutation in the NRAS gene.
  • a cancer that is characterized by at least one oncogenic mutation in the NRAS gene is a cancer that is typically associated with at least one oncogenic mutation in the NRAS gene, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic mutation in the NRAS gene.
  • the cancer is characterized by at least one oncogenic variant of N-Ras.
  • a cancer that is characterized by least one oncogenic variant of N- Ras is a cancer that is typically associated with at least one oncogenic variant of N-Ras, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic variant of N-Ras.
  • an oncogenic variant of N-Ras is a N-Ras protein that comprises at least one oncogenic mutation and that is produced as the result of the expression of a.
  • NRAS gene that comprises at least one oncogenic mutation.
  • the subject has at least one oncogenic mutation in the NRAS gene.
  • the subject has at least one tumor and/or cancerous cell that expresses an oncogenic variant of N-Ras.
  • an oncogenic mutation of N-Ras can be selected from N-Ras- G12D, N-Ras-Q61K, N-Ras-Q61R, N-Ras-Q61L and N-Ras-G13D.
  • an oncogenic mutation of N-Ras can be a mutation that induces constitutive RAF dimer activation.
  • the cancer is characterized by at least one oncogenic mutation in the NF1 gene.
  • an oncogenic mutation in the NF1 gene can be a loss- of-function mutation.
  • a cancer that is characterized by at least one oncogenic mutation in the NF1 gene is a cancer that is typically associated with at least one oncogenic mutation in the NF1 gene, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic mutation in the NF1 gene.
  • the cancer is characterized by at least one oncogenic variant of NF1.
  • a cancer that is characterized by least one oncogenic variant of NF1 is a cancer that is typically associated with at least one oncogenic variant of NF1, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic variant of N-Ras.
  • Examples of cancer also include, but are not limited to, hematologic malignancies, lymphoma, cutaneous T-cell lymphoma, peripheral T-cell lymphoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, multiple myeloma, chrome lymphocytic leukemia, chronic myeloid leukemia, acute myeloid leukemia, myelodysplastic syndromes, myelofibrosis, biliary tract cancer, hepatocellular cancer, colorectal cancer, breast cancer, lung cancer, non-small cell lung cancer, ovarian cancer, thyroid carcinoma, renal cell carcinoma, pancreatic cancer, bladder cancer, skin cancer, malignant melanoma, merkel cell carcinoma, uveal melanoma or glioblastoma multiforme.
  • the cancer is glioma (e.g., low-grade glioma) in a subject having an age of younger than 18 years.
  • glioma e.g., low-grade glioma
  • the cancer is recurrent lung cancer.
  • the cancer is melanoma and the subject has at least one tumor and/or cancerous cell that expresses an oncogenic variant of N-Ras.
  • the melanoma can be recurrent, advanced, metastatic, or any combination thereof.
  • the cancer is thyroid carcinoma and the subject has at least one tumor and/or cancerous cell that expresses and oncogenic variant of B-Raf.
  • the oncogenic variant of B-Raf is a B-Raf protein comprising at least one class I mutation, at least one class II mutation, at least one class III mutation, or any combination thereof.
  • the administration of a compound of the present disclosure does not substantially increase the amount of p-ERK in the subject.
  • the administration of a compound of the present disclosure reduces the tumor volume in the subject by at least about 10% lower, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, or at least about 99%.
  • the cancer is insensitive or resistant to treatment with one or more inhibitors of the MAPK pathways.
  • the cancer is insensitive or resistant to treatment with a BRAF inhibitor, a MEK inhibitor, or a combination thereof.
  • the cancer is insensitive or resistant to treatment with a combination comprising a BRAF inhibitor and a MEK inhibitor.
  • the cancer is insensitive to treatment with a combination comprising a BRAF inhibitor and a MEK inhibitor.
  • the cancer is resistant to treatment with a combination comprising a BRAF inhibitor and a MEK inhibitor.
  • the subject has an adverse reaction to treatment with one or more inhibitors of the MAPK pathways.
  • the subject has an adverse reaction to treatment with a BRAF inhibitor, a MEK inhibitor, or a combination thereof.
  • the subject has an adverse reaction to treatment with a combination comprising a BRAF inhibitor and a MEK inhibitor.
  • the subject has been previously administered one or more inhibitors of the MAPK pathways, and the subject has experienced disease progression despite the previous administration.
  • the subject has been previously administered a BRAF inhibitor, a MEK inhibitor, or a combination thereof, and the subject has experienced disease progression despite the previous administration.
  • the subject has been previously administered a combination comprising a BRAF inhibitor and a MEK inhibitor, and the subject has experienced disease progression despite the previous administration.
  • the subject has at least one central nervous system metastasis.
  • the at least one central nervous system metastases is stable.
  • the subject has no central nervous system metastases.
  • the subject has at least one brain metastasis. In some embodiments, the at least one brain metastasis is stable.
  • the subject has no brain metastases.
  • the subject has histiocytosis.
  • the one or more inhibitors of the MAPK pathways comprise a BRAF inhibitor, a MEK inhibitor, or any combination thereof.
  • the one or more inhibitors of the MAPK pathways comprise a combination comprising a BRAF inhibitor and a MEK inhibitor.
  • the BRAF inhibitor is vemurafenib, dabrafenib, or encorafenib.
  • the BRAF inhibitor is vemurafenib.
  • the BRAF inhibitor is dabrafenib.
  • the BRAF inhibitor is encorafenib.
  • the MEK inhibitor is trametinib, cobimetinib, or binimetinib.
  • the MEK inhibitor is trametinib.
  • the MEK inhibitor is cobimetinib.
  • the MEK inhibitor is binimetinib.
  • the compound is administered to the subject by oral administration or parenteral administration.
  • the compound is administered to the subject by oral administration.
  • a pharmaceutical composition comprising the compound is administered to the subject.
  • the pharmaceutical composition is an oral formulation.
  • a pharmaceutical composition is a tablet or a capsule.
  • the pharmaceutical composition comprises a unit dose of the compound.
  • the pharmaceutical composition comprises about 3 ⁇ 1 mg, about 3 ⁇ 0.9 mg, about 3 ⁇ 0.8 mg, about 3 ⁇ 0.7 mg, about 3 ⁇ 0.6 mg, about 3 ⁇ 0.5 mg, about 3 ⁇ 0.4 mg, about 3 ⁇ 0.3 mg, about 3 ⁇ 0.2 mg, or about 3 ⁇ 0.1 mg (e.g., about 3 mg) of the compound.
  • the compound is administered at a dosage (e.g., a daily dosage) of: about 6 ⁇ 3 mg, about 6 ⁇ 2 mg, about 6 ⁇ 1 mg, about 6 ⁇ 0.9 mg, about 6 ⁇ 0.8 mg, about 6 ⁇ 0.7 mg, about 6 ⁇ 0.6 mg, about 6 ⁇ 0.5 mg, about 6 ⁇ 0.4 mg, about 6 ⁇ 0.3 mg, about 6 ⁇ 0.2 mg, or about 6 ⁇ 0.1 mg (e.g., about 6 mg); about 12 ⁇ 6 mg, about 12 ⁇ 5 mg, about 12 ⁇ 4 mg, about 12 ⁇ 3 mg, about 12 ⁇ 2 mg, about 12 ⁇ 1 mg, about 12 ⁇ 0.9 mg, about 12 ⁇ 0.8 mg, about 12 ⁇ 0.7 mg, about 12 ⁇ 0.6 mg, about 12 ⁇ 0.5 mg, about 12 ⁇ 0.4 mg, about 12 ⁇ 0.3 mg, about 12 ⁇ 0.2 mg, or about 12 ⁇ 0.1 mg (e.g., about 12 mg); about 25 ⁇ 10 mg, about 25 ⁇ 9 mg, about 25 ⁇ 8 mg, about 25 ⁇ 7 mg, about 25 ⁇ 6 mg, about 25 ⁇ 5 mg, about 25 ⁇ 4 mg, about
  • the compound is administered at a dosage (e.g., a daily dosage) of about 6 ⁇ 3 mg, about 6 ⁇ 2 mg, about 6 ⁇ 1 mg, about 6 ⁇ 0.9 mg, about 6 ⁇ 0.8 mg, about 6 ⁇ 0.7 mg, about 6 ⁇ 0.6 mg, about 6 ⁇ 0.5 mg, about 6 ⁇ 0.4 mg, about 6 ⁇ 0.3 mg, about 6 ⁇ 0.2 mg, or about 6 ⁇ 0.1 mg (e.g., about 6 mg).
  • a dosage e.g., a daily dosage of about 6 ⁇ 3 mg, about 6 ⁇ 2 mg, about 6 ⁇ 1 mg, about 6 ⁇ 0.9 mg, about 6 ⁇ 0.8 mg, about 6 ⁇ 0.7 mg, about 6 ⁇ 0.6 mg, about 6 ⁇ 0.5 mg, about 6 ⁇ 0.4 mg, about 6 ⁇ 0.3 mg, about 6 ⁇ 0.2 mg, or about 6 ⁇ 0.1 mg (e.g., about 6 mg).
  • the compound is administered at a dosage (e.g., a daily dosage) of about 12 ⁇ 6 mg, about 12 ⁇ 5 mg, about 12 ⁇ 4 mg, about 12 ⁇ 3 mg, about 12 ⁇ 2 mg, about 12 ⁇ 1 mg, about 12 ⁇ 0.9 mg, about 12 ⁇ 0.8 mg, about 12 ⁇ 0.7 mg, about 12 ⁇ 0.6 mg, about 12 ⁇ 0.5 mg, about 12 ⁇ 0.4 mg, about 12 ⁇ 0.3 mg, about 12 ⁇ 0.2 mg, or about 12 ⁇ 0.1 mg (e.g., about 12 mg).
  • a dosage e.g., a daily dosage of about 12 ⁇ 6 mg, about 12 ⁇ 5 mg, about 12 ⁇ 4 mg, about 12 ⁇ 3 mg, about 12 ⁇ 2 mg, about 12 ⁇ 1 mg, about 12 ⁇ 0.9 mg, about 12 ⁇ 0.8 mg, about 12 ⁇ 0.7 mg, about 12 ⁇ 0.6 mg, about 12 ⁇ 0.5 mg, about 12 ⁇ 0.4 mg, about 12 ⁇ 0.3 mg, about 12 ⁇ 0.2 mg, or about 12 ⁇ 0.1 mg (e.g., about 12 mg).
  • the compound is administered at a dosage (e.g., a daily dosage) of about 50 ⁇ 20 mg, about 50 ⁇ 10 mg, about 50 ⁇ 9 mg, about 50 ⁇ 8 mg, about 50 ⁇ 7 mg, about 50 ⁇ 6 mg, about 50 ⁇ 5 mg, about 50 ⁇ 4 mg, about 50 ⁇ 3 mg, about 50 ⁇ 2 mg, or about 50 ⁇ l mg (e.g., about 50 mg).
  • a dosage e.g., a daily dosage of about 50 ⁇ 20 mg, about 50 ⁇ 10 mg, about 50 ⁇ 9 mg, about 50 ⁇ 8 mg, about 50 ⁇ 7 mg, about 50 ⁇ 6 mg, about 50 ⁇ 5 mg, about 50 ⁇ 4 mg, about 50 ⁇ 3 mg, about 50 ⁇ 2 mg, or about 50 ⁇ l mg (e.g., about 50 mg).
  • the compound is administered at a dosage (e.g., a daily dosage) of about 100 ⁇ 50 mg, about 100 ⁇ 40 mg, about 100 ⁇ 30 mg, about 100 ⁇ 20 mg, about 100 ⁇ 10 mg, about 100 ⁇ 9 mg, about 100 ⁇ 8 mg, about 100 ⁇ 7 mg, about 100 ⁇ 6 mg, about 100 ⁇ 5 mg, about 100 ⁇ 4 mg, about 100 ⁇ 3 mg, about 100 ⁇ 2 mg, or about 100 ⁇ l mg (e.g., about 100 mg).
  • a dosage e.g., a daily dosage of about 100 ⁇ 50 mg, about 100 ⁇ 40 mg, about 100 ⁇ 30 mg, about 100 ⁇ 20 mg, about 100 ⁇ 10 mg, about 100 ⁇ 9 mg, about 100 ⁇ 8 mg, about 100 ⁇ 7 mg, about 100 ⁇ 6 mg, about 100 ⁇ 5 mg, about 100 ⁇ 4 mg, about 100 ⁇ 3 mg, about 100 ⁇ 2 mg, or about 100 ⁇ l mg (e.g., about 100 mg).
  • the compound is administered at a dosage (e.g., a daily dosage) of about 150 ⁇ 70 mg, about 150 ⁇ 60 mg, about 150 ⁇ 50 mg, about 150 ⁇ 40 mg, about 150 ⁇ 30 mg, about 150 ⁇ 20 mg, about 150 ⁇ 10 mg, about 150 ⁇ 5 mg, about 150 ⁇ 4 mg, or about 150 ⁇ 3 mg (e.g., about 150 mg).
  • a dosage e.g., a daily dosage of about 150 ⁇ 70 mg, about 150 ⁇ 60 mg, about 150 ⁇ 50 mg, about 150 ⁇ 40 mg, about 150 ⁇ 30 mg, about 150 ⁇ 20 mg, about 150 ⁇ 10 mg, about 150 ⁇ 5 mg, about 150 ⁇ 4 mg, or about 150 ⁇ 3 mg (e.g., about 150 mg).
  • the compound is administered at a dosage (e.g., a daily dosage) of about 200 ⁇ 100 mg, about 200 ⁇ 90 mg, about 200 ⁇ 80 mg, about 200 ⁇ 70 mg, about 200 ⁇ 60 mg, about 200 ⁇ 50 mg, about 200 ⁇ 40 mg, about 200 ⁇ 30 mg, about 200 ⁇ 20 mg, or about 200 ⁇ 10 mg (e.g., about 200 mg).
  • a dosage e.g., a daily dosage of about 200 ⁇ 100 mg, about 200 ⁇ 90 mg, about 200 ⁇ 80 mg, about 200 ⁇ 70 mg, about 200 ⁇ 60 mg, about 200 ⁇ 50 mg, about 200 ⁇ 40 mg, about 200 ⁇ 30 mg, about 200 ⁇ 20 mg, or about 200 ⁇ 10 mg (e.g., about 200 mg).
  • the compound is administered at a dosage (e.g., a daily dosage) of about 300 ⁇ 150 mg, about 300 ⁇ 120 mg, about 300 ⁇ 100 mg, about 300 ⁇ 80 mg, about 300 ⁇ 60 mg, about 300 ⁇ 50 mg, about 300 ⁇ 40 mg, about 300 ⁇ 30 mg, about 300 ⁇ 20 mg, or about 300 ⁇ 10 mg (e.g., about 300 mg).
  • a dosage e.g., a daily dosage of about 300 ⁇ 150 mg, about 300 ⁇ 120 mg, about 300 ⁇ 100 mg, about 300 ⁇ 80 mg, about 300 ⁇ 60 mg, about 300 ⁇ 50 mg, about 300 ⁇ 40 mg, about 300 ⁇ 30 mg, about 300 ⁇ 20 mg, or about 300 ⁇ 10 mg (e.g., about 300 mg).
  • the compound is administered at a dosage (e.g., a daily dosage) of about 400 ⁇ 200 mg, about 400 ⁇ 100 mg, about 400 ⁇ 90 mg, about 400 ⁇ 80 mg, about 400 ⁇ 70 mg, about 400 ⁇ 60 mg, about 400 ⁇ 50 mg, about 400 ⁇ 40 mg, about 400 ⁇ 30 mg, about 400 ⁇ 20 mg, or about 400 ⁇ 10 mg (e.g., about 400 mg).
  • a dosage e.g., a daily dosage
  • the compound is administered at a dosage (e.g., a daily dosage) of about 600 ⁇ 300 mg, about 600 ⁇ 200 mg, about 600 ⁇ 100 mg, about 600 ⁇ 90 mg, about 600 ⁇ 80 mg, about 600 ⁇ 70 mg, about 600 ⁇ 60 mg, about 600 ⁇ 50 mg, about 600 ⁇ 40 mg, about 600 ⁇ 30 mg, about 600 ⁇ 20 mg, or about 600 ⁇ 10 mg (e.g., about 600 mg).
  • a dosage e.g., a daily dosage of about 600 ⁇ 300 mg, about 600 ⁇ 200 mg, about 600 ⁇ 100 mg, about 600 ⁇ 90 mg, about 600 ⁇ 80 mg, about 600 ⁇ 70 mg, about 600 ⁇ 60 mg, about 600 ⁇ 50 mg, about 600 ⁇ 40 mg, about 600 ⁇ 30 mg, about 600 ⁇ 20 mg, or about 600 ⁇ 10 mg (e.g., about 600 mg).
  • the compound is administered at a dosage (e.g., a daily dosage) of about 800 ⁇ 400 mg, about 800 ⁇ 300 mg, about 800 ⁇ 200 mg, about 800 ⁇ 100 mg, about 800 ⁇ 90 mg, about 800 ⁇ 80 mg, about 800 ⁇ 70 mg, about 800 ⁇ 60 mg, about 800 ⁇ 50 mg, about 800 ⁇ 40 mg, about 800 ⁇ 30 mg, about 800 ⁇ 20 mg, or about 800 ⁇ 10 mg (e.g., about 800 mg).
  • a dosage e.g., a daily dosage of about 800 ⁇ 400 mg, about 800 ⁇ 300 mg, about 800 ⁇ 200 mg, about 800 ⁇ 100 mg, about 800 ⁇ 90 mg, about 800 ⁇ 80 mg, about 800 ⁇ 70 mg, about 800 ⁇ 60 mg, about 800 ⁇ 50 mg, about 800 ⁇ 40 mg, about 800 ⁇ 30 mg, about 800 ⁇ 20 mg, or about 800 ⁇ 10 mg (e.g., about 800 mg).
  • the compound is administered at a dosage (e.g., a daily dosage) of about 1000 ⁇ 500 mg, about 1000 ⁇ 400 mg, about 1000 ⁇ 300 mg, about 1000 ⁇ 200 mg, about 1000 ⁇ 100 mg, about 1000 ⁇ 90 mg, about 1000 ⁇ 80 mg, about 1000 ⁇ 70 mg, about 1000 ⁇ 60 mg, about 1000 ⁇ 50 mg, about 1000 ⁇ 40 mg, about 1000 ⁇ 30 mg, about 1000 ⁇ 20 mg, or about 1000 ⁇ 10 mg (e.g., about 1000 mg).
  • a dosage e.g., a daily dosage of about 1000 ⁇ 500 mg, about 1000 ⁇ 400 mg, about 1000 ⁇ 300 mg, about 1000 ⁇ 200 mg, about 1000 ⁇ 100 mg, about 1000 ⁇ 90 mg, about 1000 ⁇ 80 mg, about 1000 ⁇ 70 mg, about 1000 ⁇ 60 mg, about 1000 ⁇ 50 mg, about 1000 ⁇ 40 mg, about 1000 ⁇ 30 mg, about 1000 ⁇ 20 mg, or about 1000 ⁇ 10 mg (e.g., about 1000 mg).
  • the compound is administered at a dosage (e.g., a daily dosage) of about 1200 ⁇ 600 mg, about 1200 ⁇ 500 mg, about 1200 ⁇ 400 mg, about 1200 ⁇ 300 mg, about 1200 ⁇ 200 mg, about 1200 ⁇ 100 mg, about 1200 ⁇ 90 mg, about 1200 ⁇ 80 mg, about 1200 ⁇ 70 mg, about 1200 ⁇ 60 mg, about 1200 ⁇ 50 mg, about 1200 ⁇ 40 mg, about 1200 ⁇ 30 mg, about 1200 ⁇ 20 mg, or about 1200 ⁇ 10 mg (e.g., about 1200 mg).
  • a dosage e.g., a daily dosage of about 1200 ⁇ 600 mg, about 1200 ⁇ 500 mg, about 1200 ⁇ 400 mg, about 1200 ⁇ 300 mg, about 1200 ⁇ 200 mg, about 1200 ⁇ 100 mg, about 1200 ⁇ 90 mg, about 1200 ⁇ 80 mg, about 1200 ⁇ 70 mg, about 1200 ⁇ 60 mg, about 1200 ⁇ 50 mg, about 1200 ⁇ 40 mg, about 1200 ⁇ 30 mg, about 1200 ⁇ 20 mg, or about 1200
  • the compound is administered at a dosage (e.g., a daily dosage) of: about 0.2 ⁇ 0.2 mg/kg, about 0.2 ⁇ 0.1 mg/kg, about 0.2 ⁇ 0.09 mg/kg, about 0.2 ⁇ 0.08 mg/kg, about 0.2 ⁇ 0.07 mg/kg, about 0.2 ⁇ 0.06 mg/kg, about 0.2 ⁇ 0.05 mg/kg, about 0.2 ⁇ 0.04 mg/kg, about 0.2 ⁇ 0.03 mg/kg, about 0.2 ⁇ 0.02 mg/kg, or about 0.2 ⁇ 0.01 mg/kg (e.g., about 0.2 mg/kg); about 0.4 ⁇ 0.2 mg/kg, about 0.4 ⁇ 0.1 mg/kg, about 0.4 ⁇ 0.09 mg/kg, about 0.4 ⁇ 0.08 mg/kg, about 0.4 ⁇ 0.07 mg/kg, about 0.4 ⁇ 0.06 mg/kg, about 0.4 ⁇ 0.05 mg/kg, about 0.4 ⁇ 0.04 mg/kg, about 0.4 ⁇ 0.03 mg/kg, about 0.4 ⁇ 0.02 mg/kg, or about 0.4 ⁇ 0.01 mg/kg (e.g.,
  • the compound is administered at a dosage (e.g., a daily dosage) of about 0.2 ⁇ 0.2 mg/kg, about 0.2 ⁇ 0.1 mg/kg, about 0.2 ⁇ 0.09 mg/kg, about 0.2 ⁇ 0.08 mg/kg, about 0.2 ⁇ 0.07 mg/kg, about 0.2 ⁇ 0.06 mg/kg, about 0.2 ⁇ 0.05 mg/kg, about 0.2 ⁇ 0.04 mg/kg, about 0.2 ⁇ 0.03 mg/kg, about 0.2 ⁇ 0.02 mg/kg, or about 0.2 ⁇ 0.01 mg/kg (e.g., about 0.2 mg/kg).
  • a dosage e.g., a daily dosage
  • the pharmaceutical composition has a unit dose strength of about 1 mg, about 2 mg, about 3 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 75 mg, or about 100 mg.
  • the compound is administered with one or more drug holidays. [0229] In some embodiments, the compound is administered without any drug holiday.
  • the compound is administered once daily (QD).
  • the compound is administered for longer than 210 days.
  • the present disclosure provides a method of treating or preventing cancer in a subject, the method comprising administering to the subject a combination comprising a compound of the present disclosure (e.g., in a therapeutically effective amount) and one or more additional therapeutic agents (e.g., in a therapeutically effective amount).
  • the present disclosure provides a method of treating cancer in a subject, the method comprising administering to the subject a combination comprising a compound of the present disclosure (e.g., in a therapeutically effective amount) and additional therapeutic agents (e.g., in a therapeutically effective amount).
  • the present disclosure provides a combination comprising a compound of the present disclosure and one or more additional therapeutic agents, for treating cancer in a subject.
  • the present disclosure provides a use of a combination comprising a compound of the present disclosure and one or more additional therapeutic agents, in the manufacture of a medicament for treating or preventing cancer in a subject.
  • the present disclosure provides a use of a combination comprising a compound of the present disclosure and additional therapeutic agents, in the manufacture of a medicament for treating cancer in a subject.
  • the one or more additional therapeutic agents comprise one or more SHP2 (src homology-2 domain-containing protein tyrosine phosphatase-2) inhibitors, one or more S0S1 inhibitors, one or more KRAS (kirsten rat sarcoma virus) inhibitors, one or more ERK (extracellular signal-regulated kinase) inhibitors, one or more immune checkpoint inhibitors, one or more chemotherapies, one or more EGFR (epidermal growth factor receptor) inhibitors, one or more MET (mesenchymal-epithelial transition) inhibitors, one or more TEAD (transcriptional enhanced associate domain) inhibitors, one or more YAP (yes- associated protein) inhibitors, one or more PI3K (phosphoinositide 3 -kinase) inhibitors, one or more mTOR (mammalian target of rapamycin) inhibitors, one or more metabolic inhibitors, or one or more MEK (mitogen-activated protein
  • SHP2 src
  • the one or more additional therapeutic agents comprise one or more SHP2 inhibitors.
  • the one or more SHP2 inhibitors comprises JAB-3068, JAB- 3312, TNO-155, RLY-1971, or RMC-4630.
  • the one or more additional therapeutic agents comprise one or more S0S1 inhibitors.
  • the one or more S0S1 inhibitors comprises BI-1701963, BI- 1703880, or MRTX0902.
  • the one or more additional therapeutic agents comprise one or more KRAS inhibitors.
  • the one or more KRAS inhibitors comprises sotorasib, adagrasib, LY3537982, divarasib, JDQ443, BI-1823911, MRTX1133, RMC-9805, or RMC- 6236.
  • the one or more additional therapeutic agents comprise one or more ERK inhibitors.
  • the one or more ERK inhibitors comprises ulixertinib, MK- 8353, LY3214996, ASTX029, ASN007, LTT462, or KO-947.
  • the one or more additional therapeutic agents comprise one or more immune checkpoint inhibitors.
  • the one or more immune checkpoint inhibitors comprises pembrolizumab, ipilimumab, nivolumab, or atezolizumab.
  • the one or more additional therapeutic agents comprise one or more chemotherapies.
  • the one or more additional therapeutic agents comprise one or more EGFR inhibitors.
  • the one or more additional therapeutic agents comprise one or more MET inhibitors.
  • the one or more additional therapeutic agents comprise one or more TEAD inhibitors.
  • the one or more TEAD inhibitors comprises VT3989, IK-930, or IAG933.
  • the one or more additional therapeutic agents comprise one or more mTOR inhibitors.
  • the present disclosure provides a combination comprising a compound of the present disclosure and one or more MEK inhibitors.
  • the present disclosure provides a method of treating or preventing cancer in a subject, the method comprising administering to the subject a combination comprising a compound of the present disclosure (e.g., in a therapeutically effective amount) and trametinib (e.g., in a therapeutically effective amount).
  • the present disclosure provides a method of treating or preventing cancer in a subject, the method comprising administering to the subject a combination comprising a compound of the present disclosure (e.g., in a therapeutically effective amount) and cobimetinib (e.g., in a therapeutically effective amount).
  • the present disclosure provides a method of treating or preventing cancer in a subject, the method comprising administering to the subject a combination comprising a compound of the present disclosure (e.g., in a therapeutically effective amount) and binimetinib (e.g., in a therapeutically effective amount).
  • the present disclosure provides a method of treating cancer in a subject, the method comprising administering to the subject a combination comprising a compound of the present disclosure (e.g., in a therapeutically effective amount) and one or more inhibitors of the MAPK pathways (e.g., in a therapeutically effective amount).
  • the present disclosure provides a method of treating cancer in a subject, the method comprising administering to the subject a combination comprising : a compound of the present disclosure (e.g., in a therapeutically effective amount); and one or more of trametinib, cobimetinib, or binimetinib (e.g., in a therapeutically effective amount).
  • the present disclosure provides a method of treating cancer in a subject, the method comprising administering to the subject a combination comprising a compound of the present disclosure (e.g., in a therapeutically effective amount) and trametinib (e.g., in a therapeutically effective amount).
  • the present disclosure provides a method of treating cancer in a subject, the method comprising administering to the subject a combination comprising a compound of the present disclosure (e.g., in a therapeutically effective amount) and cobimetinib (e.g., in a therapeutically effective amount).
  • the present disclosure provides a method of treating cancer in a subject, the method comprising administering to the subject a combination comprising a compound of the present disclosure (e.g., in a therapeutically effective amount) and binimetinib (e.g., in a therapeutically effective amount).
  • the present disclosure provides a combination comprising a compound of the present disclosure and one or more inhibitors of the MAPK pathways, for treating or preventing cancer in a subject.
  • the present disclosure provides a combination comprising a compound of the present disclosure and cobimetinib, for treating or preventing cancer in a subject.
  • the present disclosure provides a combination comprising a compound of the present disclosure and binimetinib, for treating or preventing cancer in a subject.
  • the present disclosure provides a combination comprising a compound of the present disclosure and one or more inhibitors of the MAPK pathways, for treating cancer in a subject.
  • the present disclosure provides a combination comprising: a compound of the present disclosure, and one or more of trametinib, cobimetinib, or binimetinib, for treating cancer in a subject.
  • the present disclosure provides a combination comprising a compound of the present disclosure and trametinib, for treating cancer in a subject.
  • the present disclosure provides a combination comprising a compound of the present disclosure and cobimetinib, for treating cancer in a subject.
  • the present disclosure provides a combination comprising a compound of the present disclosure and binimetinib, for treating cancer in a subject.
  • the present disclosure provides a use of a combination comprising a compound of the present disclosure and one or more inhibitors of the MAPK pathways, in the manufacture of a medicament for treating or preventing cancer in a subject.
  • the present disclosure provides a use of a combination comprising: a compound of the present disclosure, and one or more of trametinib, cobimetinib, or binimetinib, in the manufacture of a medicament for treating or preventing cancer in a subject.
  • the present disclosure provides a use of a combination comprising a compound of the present disclosure and binimetinib, in the manufacture of a medicament for treating or preventing cancer in a subject.
  • the present disclosure provides a use of a combination comprising a compound of the present disclosure and one or more inhibitors of the MAPK pathways, in the manufacture of a medicament for treating cancer in a subject.
  • the present disclosure provides a use of a combination comprising a compound of the present disclosure and trametinib, in the manufacture of a medicament for treating cancer in a subject.
  • the present disclosure provides a use of a combination comprising a compound of the present disclosure and cobimetinib, in the manufacture of a medicament for treating cancer in a subject.
  • the compound and the one or more inhibitors of the MAPK pathways are administered sequentially or in alternation.
  • binimetinib is administered once daily.
  • binimetinib is administered twice daily.
  • the compound is administered at a dosage (e.g., a daily dosage) of about 6 ⁇ 3 mg, about 6 ⁇ 2 mg, about 6 ⁇ 1 mg, about 6 ⁇ 0.9 mg, about 6 ⁇ 0.8 mg, about 6 ⁇ 0.7 mg, about 6 ⁇ 0.6 mg, about 6 ⁇ 0.5 mg, about 6 ⁇ 0.4 mg, about 6 ⁇ 0.3 mg, about 6 ⁇ 0.2 mg, or about 6 ⁇ 0.1 mg (e.g., about 6 mg); and binimetinib is administered at a dosage (e.g., a daily dosage) of about 60 ⁇ 30 mg, about 60 ⁇ 20 mg, about 60 ⁇ 10 mg, about 60 ⁇ 9 mg, about 60 ⁇ 8 mg, about 60 ⁇ 7 mg, about 60 ⁇ 6 mg, about 60 ⁇ 5 mg, about 60 ⁇ 4 mg, about 60 ⁇ 3 mg, about 60 ⁇ 2 mg, or about 60 ⁇ l mg (e.g., about 60 mg); or about 90 ⁇ 50 mg, about 90 ⁇ 40 mg, about 90 ⁇ 30 mg, about 90 ⁇ 20 mg, about 90 ⁇ 10 mg, about 90 ⁇ 9 mg,
  • the compound is administered at a dosage (e.g., a daily dosage) of about 300 ⁇ 150 mg, about 300 ⁇ 120 mg, about 300 ⁇ 100 mg, about 300 ⁇ 80 mg, about 300 ⁇ 60 mg, about 300 ⁇ 50 mg, about 300 ⁇ 40 mg, about 300 ⁇ 30 mg, about 300 ⁇ 20 mg, or about 300 ⁇ 10 mg (e.g., about 300 mg); and binimetinib is administered at a dosage (e.g., a daily dosage) of about 60 ⁇ 30 mg, about 60 ⁇ 20 mg, about 60 ⁇ 10 mg, about 60 ⁇ 9 mg, about 60 ⁇ 8 mg, about 60 ⁇ 7 mg, about 60 ⁇ 6 mg, about 60 ⁇ 5 mg, about 60 ⁇ 4 mg, about 60 ⁇ 3 mg, about 60 ⁇ 2 mg, or about 60 ⁇ l mg (e.g., about 60 mg); or about 90 ⁇ 50 mg, about 90 ⁇ 40 mg, about 90 ⁇ 30 mg, about 90 ⁇ 20 mg, about 90 ⁇ 10 mg, about 90 ⁇ 9 mg, about 90 ⁇ 8 mg, about 90 ⁇ 7 mg,
  • the compound is administered at a dosage (e.g., a daily dosage) of about 400 ⁇ 200 mg, about 400 ⁇ 100 mg, about 400 ⁇ 90 mg, about 400 ⁇ 80 mg, about 400 ⁇ 70 mg, about 400 ⁇ 60 mg, about 400 ⁇ 50 mg, about 400 ⁇ 40 mg, about 400 ⁇ 30 mg, about 400 ⁇ 20 mg, or about 400 ⁇ 10 mg (e.g., about 400 mg); and binimetinib is administered at a dosage (e.g., a daily dosage) of about 60 ⁇ 30 mg, about 60 ⁇ 20 mg, about 60 ⁇ 10 mg, about 60 ⁇ 9 mg, about 60 ⁇ 8 mg, about 60 ⁇ 7 mg, about 60 ⁇ 6 mg, about 60 ⁇ 5 mg, about 60 ⁇ 4 mg, about 60 ⁇ 3 mg, about 60 ⁇ 2 mg, or about 60 ⁇ l mg (e.g., about 60 mg); or about 90 ⁇ 50 mg, about 90 ⁇ 40 mg, about 90 ⁇ 30 mg, about 90 ⁇ 20 mg, about 90 ⁇ 10 mg, about 90 ⁇ 9 mg, about 90 ⁇ 8 mg,
  • the compound is administered at a dosage (e.g., a daily dosage) of about 600 ⁇ 300 mg, about 600 ⁇ 200 mg, about 600 ⁇ 100 mg, about 600 ⁇ 90 mg, about 600 ⁇ 80 mg, about 600 ⁇ 70 mg, about 600 ⁇ 60 mg, about 600 ⁇ 50 mg, about 600 ⁇ 40 mg, about 600 ⁇ 30 mg, about 600 ⁇ 20 mg, or about 600 ⁇ 10 mg (e.g., about 600 mg); and binimetinib is administered at a dosage (e.g., a daily dosage) of about 60 ⁇ 30 mg, about 60 ⁇ 20 mg, about 60 ⁇ 10 mg, about 60 ⁇ 9 mg, about 60 ⁇ 8 mg, about 60 ⁇ 7 mg, about 60 ⁇ 6 mg, about 60 ⁇ 5 mg, about 60 ⁇ 4 mg, about 60 ⁇ 3 mg, about 60 ⁇ 2 mg, or about 60 ⁇ l mg (e.g., about 60 mg); or about 90 ⁇ 50 mg, about 90 ⁇ 40 mg, about 90 ⁇ 30 mg, about 90 ⁇ 20 mg, about 90 ⁇ 10 mg, about 90 ⁇ 9 mg,
  • the compound is administered at a dosage (e.g., a daily dosage) of about 1000 ⁇ 500 mg, about 1000 ⁇ 400 mg, about 1000 ⁇ 300 mg, about 1000 ⁇ 200 mg, about 1000 ⁇ 100 mg, about 1000 ⁇ 90 mg, about 1000 ⁇ 80 mg, about 1000 ⁇ 70 mg, about 1000 ⁇ 60 mg, about 1000 ⁇ 50 mg, about 1000 ⁇ 40 mg, about 1000 ⁇ 30 mg, about 1000 ⁇ 20 mg, or about 1000 ⁇ 10 mg (e.g., about 1000 mg); and binimetinib is administered at a dosage (e.g., a daily dosage) of about 60 ⁇ 30 mg, about 60 ⁇ 20 mg, about 60 ⁇ 10 mg, about 60 ⁇ 9 mg, about 60 ⁇ 8 mg, about 60 ⁇ 7 mg, about 60 ⁇ 6 mg, about 60 ⁇ 5 mg, about 60 ⁇ 4 mg, about 60 ⁇ 3 mg, about 60 ⁇ 2 mg, or about 60 ⁇ l mg (e.g., about 60 mg); or about 90 ⁇ 50 mg, about 90 ⁇ 40 mg, about 90 ⁇ 30 mg, about 90 ⁇ 20 mg,
  • the one or more additional therapeutic agents comprise chemotherapeutic agents, therapeutic antibodies, and radiation treatment.
  • chemotherapeutics are presently known in the art.
  • the chemotherapeutic is selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti -hormones, angiogenesis inhibitors, and anti-androgens.
  • Non-limiting examples are chemotherapeutic agents, cytotoxic agents, and non-peptide small molecules such as Gleevec® (Imatinib Mesylate), Kyprolis® (carfilzomib), Velcade® (bortezomib), Casodex (bicalutamide), Iressa® (gefitinib), and Adriamycin as well as a host of chemotherapeutic agents.
  • Non-limiting examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclosphosphamide (CYTOXANTMTM); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine; nitrogen mustards such as chlorambucil, chlomaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such
  • anti-hormonal agents that act to regulate or inhibit hormone action on tumors
  • anti-estrogens including for example tamoxifen, (Nolvadex T n), raloxifene, aromatase inhibiting 4(5)-imidazoles, 4- hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP- 16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinor
  • the one or more additional therapeutic agents comprise commonly prescribed anti-cancer drugs such as Herceptin®, Avastin®, Erbitux®, Rituxan®, Taxol®, Arimidex®, Taxotere®, ABVD, AVICINE, Abagovomab, Acridine carboxamide, Adecatumumab, 17-N-Allylamino-17-demethoxygeldanamycin, Alpharadin, Alvocidib, 3- Aminopyridine-2-carboxaldehyde thiosemicarbazone, Amonafide, Anthracenedione, Anti- CD22 immunotoxins, Antineoplastic, Antitumorigenic herbs, Apaziquone, Atiprimod, Azathioprine, Belotecan, Bendamustine, BIBW 2992, Biricodar, Brostallicin, Bryostatin, Buthionine sulfoximine, CBV (chemotherapy), Calyculin,
  • anti-cancer drugs such
  • the one or more additional therapeutic agents comprise radiation therapy for inhibiting abnormal cell growth or treating the hyperproliferative disorder in the mammal.
  • Techniques for administering radiation therapy are known in the art.
  • Radiation therapy can be administered through one of several methods, or a combination of methods, including without limitation external-beam therapy, internal radiation therapy, implant radiation, stereotactic radiosurgery, systemic radiation therapy, radiotherapy and permanent or temporary interstitial brachytherapy.
  • brachytherapy refers to radiation therapy delivered by a spatially confined radioactive material inserted into the body at or near a tumor or other proliferative tissue disease site.
  • the term is intended without limitation to include exposure to radioactive isotopes (e.g. At-211, 1-131, 1-125, Y- 90, Re-186, Re-188, Sm-153, Bi-212, P-32, and radioactive isotopes of Lu).
  • Suitable radiation sources for use as a cell conditioner of the present disclosure include both solids and liquids.
  • the radiation source can be a radionuclide, such as 1-125, 1- 131, Yb-169, Ir-192 as a solid source, 1-125 as a solid source, or other radionuclides that emit photons, beta particles, gamma radiation, or other therapeutic rays.
  • the radioactive material can also be a fluid made from any solution of radionuclide(s), e.g., a solution of 1-125 or 1- 131, or a radioactive fluid can be produced using a slurry of a suitable fluid containing small particles of solid radionuclides, such as Au-198, Y-90.
  • the radionuclide(s) can be embodied in a gel or radioactive micro spheres.
  • Anti-angiogenesis agents such as MMP-2 (matrix-metalloproteinase 2) inhibitors, MMP-9 (matrix-metalloprotienase 9) inhibitors, and COX-11 (cyclooxygenase 11) inhibitors, can be used in conjunction with a compound of the disclosure and pharmaceutical compositions described herein.
  • Anti-angiogenesis agents include, for example, rapamycin, temsirolimus (CCI-779), everolimus (RAD001), sorafenib, sunitinib, and bevacizumab.
  • Examples of useful COX-II inhibitors include alecoxib, valdecoxib, and rofecoxib.
  • MMP-2 and MMP-9 inhibitors are those that have little or no activity inhibiting MMP-1. More preferred, are those that selectively inhibit MMP- 2 and/or AMP-9 relative to the other matrix-metalloproteinases (i. e., MAP-1, MMP-3, MMP- 4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, andMMP-13).
  • MMP inhibitors useful in the disclosure are AG-3340, RO 32-3555, and RS 13-0830.
  • the one or more additional therapeutic agents comprise anti- neoplastic agents, such as acemannan, aclarubicin, aldesleukin, alemtuzumab, alitretinoin, altretamine, amifostine, aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, ANCER, ancestim, ARGLABIN, arsenic trioxide, BAM 002 (Novelos), bexarotene, bicalutamide, broxuridine, capecitabine, celmoleukin, cetrorelix, cladribine, clotrimazole, cytarabine ocfosfate, DA 3030 (Dong- A), daclizumab, denileukin diftitox, deslorelin, dexrazoxane, dilazep, docetaxel, docosanol
  • the one or more additional therapeutic agents comprise VEGFR inhibitors, including compounds described in the following patents and patent applications: U.S. Patent No. 6,258,812, US 2003/0105091, WO/2001/037820, U.S. Patent No. 6,235,764, WO/2001/032651, U.S. Patent Nos.
  • the one or more additional therapeutic agents comprise at least one anti-angiogenic agent.
  • Agents are inclusive of, but not limited to, in vitro synthetically prepared chemical compositions, antibodies, antigen binding regions, radionuclides, and combinations and conjugates thereof.
  • An agent can be an agonist, antagonist, allosteric modulator, toxin or, more generally, may act to inhibit or stimulate its target (e.g., receptor or enzyme activation or inhibition), and thereby promote cell death or arrest cell growth.
  • anti-angiogenic agents include ERBITUXTM (IMC-C225), KDR (kinase domain receptor) inhibitory agents (e.g., antibodies and antigen binding regions that specifically bind to the kinase domain receptor), anti-VEGF agents (e.g., antibodies or antigen binding regions that specifically bind VEGF, or soluble VEGF receptors or a ligand binding region thereof) such as AVASTINTM or VEGF-TRAPTM, and anti-VEGF receptor agents (e.g., antibodies or antigen binding regions that specifically bind thereto), EGFR inhibitory agents (e.g., antibodies or antigen binding regions that specifically bind thereto) such as Vectibix (panitumumab), IRESSATM (gefitinib), TARCEVATM (erlotinib), anti-Angl and anti-Ang2 agents (e.g., antibodies or antigen binding regions specifically binding thereto or to their receptors, e.g., Tie2/
  • compositions of the present invention can also include one or more agents (e.g., antibodies, antigen binding regions, or soluble receptors) that specifically bind and inhibit the activity of growth factors, such as antagonists of hepatocyte growth factor (HGF, also known as Scatter Factor), and antibodies or antigen binding regions that specifically bind its receptor “c-met”.
  • agents e.g., antibodies, antigen binding regions, or soluble receptors
  • HGF hepatocyte growth factor
  • c-met antibodies or antigen binding regions that specifically bind its receptor “c-met”.
  • anti-angiogenic agents include Campath, IL-8, B-FGF, Tek antagonists (Ceretti et al., U.S. Publication No. 2003/0162712; U.S. Pat. No. 6,413,932), anti-TWEAK agents (e.g., specifically binding antibodies or antigen binding regions, or soluble TWEAK receptor antagonists; see, Wiley, U.S. Pat. No. 6,727,225), ADAM distintegrin domain to antagonize the binding of integrin to its ligands (Fanslow et al., U.S. Publication No.
  • anti-eph receptor and/or anti-ephrin antibodies or antigen binding regions U.S. Pat. Nos. 5,981,245; 5,728,813; 5,969,110; 6,596,852; 6,232,447; 6,057,124 and patent family members thereof
  • anti-PDGF-BB antagonists e.g., specifically binding antibodies or antigen binding regions
  • PDGFR kinase inhibitory agents e.g., antibodies or antigen binding regions that specifically bind thereto.
  • Additional anti-angiogenic/anti-tumor agents include: SD-7784 (Pfizer, USA); cilengitide. (Merck KGaA, Germany, EPO 770622); pegaptanib octasodium, (Gilead Sciences, USA); Alphastatin, (BioActa, UK); M-PGA, (Celgene, USA, U.S. Pat. No. 5,712,291); ilomastat, (Arriva, USA, U.S. Pat. No. 5,892,112); emaxanib, (Pfizer, USA, U.S. Pat. No.
  • vatalanib (Novartis, Switzerland); 2-methoxyestradiol, (EntreMed, USA); TLC ELL- 12, (Elan, Ireland); anecortave acetate, (Alcon, USA); alpha-D148 Mab, (Amgen, USA); CEP-7055, (Cephalon, USA); anti-Vn Mab, (Crucell, Netherlands) DAC: anti angiogenic, (ConjuChem, Canada); Angiocidin, (InKine Pharmaceutical, USA); KM-2550, (Kyowa Hakko, Japan); SU-0879, (Pfizer, USA); CGP-79787, (Novartis, Switzerland, EP 970070); ARGENT technology, (Ariad, USA); YIGSR- Stealth, (Johnson & Johnson, USA); fibrinogen- E fragment, (BioActa, UK); angiogenesis inhibitor, (Trigen, UK); TBC-1635, (Encysive Pharmaceuticals, USA); SC-2
  • Autophagy inhibitors include, but are not limited to chloroquine, 3 -methyladenine, hydroxychloroquine (PlaquenilTM), bafilomycin Al, 5-amino-4-imidazole carboxamide riboside (AICAR), okadaic acid, autophagy-suppressive algal toxins which inhibit protein phosphatases of type 2A or type 1, analogues of cAMP, and drugs which elevate cAMP levels such as adenosine, LY204002, N6-mercaptopurine riboside, and vinblastine.
  • antisense or siRNA that inhibits expression of proteins including but not limited to ATG5 (which are implicated in autophagy), may also be used.
  • chemotherapeutic agents may include mechlorethamine, camptothecin, ifosfamide, tamoxifen, raloxifene, gemcitabine, navelbine, sorafenib, or any analog or derivative variant of the foregoing.
  • the one or more additional therapeutic agents comprise a steroid.
  • Suitable steroids may include, but are not limited to, 21 -acetoxypregnenolone, alclometasone, algestone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, desonide, desoximetasone, dexamethasone, diflorasone, diflucortolone, difuprednate, enoxolone, fluazacort, flucloronide, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluorometholone, fluperolone acetate, flupredn
  • the compounds of the present invention can also be used in combination with additional pharmaceutically active agents that treat nausea.
  • agents that can be used to treat nausea include: dronabinol; granisetron; metoclopramide; ondansetron; and prochlorperazine; or a pharmaceutically acceptable salt thereof.
  • the one or more additional therapeutic agents comprise a compound that disrupts or inhibits RAS-RAF-ERK or PI3K-AKT-TOR signaling pathways.
  • the additional pharmaceutically active compound is a PD-1 and PD- L1 antagonist.
  • the compounds or pharmaceutical compositions of the disclosure can also be used in combination with an amount of one or more substances selected from EGFR inhibitors, MEK inhibitors, PI3K inhibitors, AKT inhibitors, TOR inhibitors, Mcl-1 inhibitors, BCL-2 inhibitors, SHP2 inhibitors, proteasome inhibitors, and immune therapies, including monoclonal antibodies, immunomodulatory imides (IMiDs), anti-PD-1, anti-PDL-1, anti- CTLA4, anti-LAGl, and anti-OX40 agents, GITR agonists, CAR-T cells, and BiTEs.
  • IMDs immunomodulatory imides
  • EGFR inhibitors include, but are not limited to, small molecule antagonists, antibody inhibitors, or specific antisense nucleotide or siRNA.
  • Useful antibody inhibitors of EGFR include cetuximab (Erbitux), panitumumab (Vectibix), zalutumumab, nimotuzumab, and matuzumab.
  • Small molecule antagonists of EGFR include gefitinib, erlotinib (Tarceva), and most recently, lapatinib (TykerB). See e.g., Yan L, et.
  • Non-limiting examples of small molecule EGFR inhibitors include any of the EGFR inhibitors described in the following patent publications, and all pharmaceutically acceptable salts of said EGFR inhibitors: European Patent Application EP 520722, published Dec. 30, 1992; European Patent Application EP 566226, published Oct. 20, 1993; PCT International Publication WO 96/33980, published Oct. 31, 1996; U.S. Pat. No. 5,747,498, issued May 5, 1998; PCT International Publication WO 96/30347, published Oct. 3, 1996; European Patent Application EP 787772, published Aug. 6, 1997; PCT International Publication WO 97/30034, published Aug. 21, 1997; PCT International Publication WO 97/30044, published Aug.
  • Antibody -based EGFR inhibitors include any anti -EGFR antibody or antibody fragment that can partially or completely block EGFR activation by its natural ligand.
  • Nonlimiting examples of antibody-based EGFR inhibitors include those described in Modjtahedi, H., et al., 1993, Br. J. Cancer 67:247-253; Teramoto, T., et al., 1996, Cancer 77:639-645; Goldstein et al., 1995, Clin. Cancer Res. 1 : 1311-1318; Huang, S. M., et al., 1999, Cancer Res. 15:59(8): 1935-40; and Yang, X., et al., 1999, Cancer Res. 59: 1236-1243.
  • the EGFR inhibitor can be monoclonal antibody Mab E7.6.3 (Yang, 1999 supra), or Mab C225 (ATCC Accession No. HB-8508), or an antibody or antibody fragment having the binding specificity thereof.
  • MEK inhibitors include, but are not limited to, CI-1040, AZD6244, PD318088, PD98059, PD334581, RDEA119, ARRY-142886, ARRY-438162, and PD-325901.
  • PI3K inhibitors include, but are not limited to, wortmannin, 17-hydroxywortmannin analogs described in WO 06/044453, 4-[2-(lH-Indazol-4-yl)-6-[[4-(methylsulfonyl)piperazin- l-yl]methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine (also known as GDC 0941 and described in PCT Publication Nos.
  • LY294002 (2-(4-Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one available from Axon Medchem), PI 103 hydrochloride (3-[4-(4-morpholinylpyrido-[3',2':4,5]furo[3,2- d]pyrimidin-2-yl]phenol hydrochloride available from Axon Medchem), PIK 75 (N'-[(lE)-(6- bromoimidazo[l,2-a]pyridin-3-yl)methylene]-N,2-dimethyl-5-nitrobenzenesulfono-hydrazide hydrochloride available from Axon Medchem), PIK 90 (N-(7,8-dimethoxy-2,3- dihydroimidazo[l,2-c]quinazolin-5-yl)-nicotinamide available from Axon Medchem), GDC- 0941 bismesylate (2-(4-Morpholin
  • PI3K inhibitors include demethoxyviridin, perifosine, CAL101, PX- 866, BEZ235, SF1126, INK1117, IPI-145, BKM120, XL147, XL765, Palomid 529, GSK1059615, ZSTK474, PWT33597, IC87114, TG100-115, CAL263, PI-103, GNE-477, CUDC-907, and AEZS-136.
  • AKT inhibitors include, but are not limited to, Akt-1-1 (inhibits Aktl) (Barnett et al. (2005) Biochem. J., 385 (Pt. 2), 399-408); Akt-1-1, 2 (inhibits Akl and 2) (Barnett et al. (2005) Biochem. J 385 (Pt. 2), 399-408); API-59CJ-Ome (e.g., Jin et al. (2004) Br. J. Cancer 91, 1808-12); l-H-imidazo[4,5-c]pyridinyl compounds (e.g., W005011700); indole- 3-carbinol and derivatives thereof (e.g., U.S. Pat. No.
  • TOR inhibitors include, but are not limited to, inhibitors include AP-23573, CCI-779, everolimus, RAD-001, rapamycin, temsirolimus, ATP-competitive TORC1/TORC2 inhibitors, including PI- 103, PP242, PP30 and Torin 1.
  • Other TOR inhibitors in FKBP12 enhancer include rapamycins and derivatives thereof, including: CCI-779 (temsirolimus), RAD001 (Everolimus; WO 9409010) and AP23573; rapalogs, e.g. as disclosed in WO 98/02441 and WO 01/14387, e.g.
  • AP23573, AP23464, or AP23841 40-(2-hydroxyethyl)rapamycin, 40-[3- hydroxy(hydroxymethyl)methylpropanoate]-rapamycin (also called CC1779), 40-epi- (tetrazolyt)-rapamycin (also called ABT578), 32-deoxorapamycin, 16-pentynyloxy-32(S)- dihydrorapanycin, and other derivatives disclosed in WO 05005434; derivatives disclosed in U.S. Pat. No. 5,258,389, WO 94/090101, WO 92/05179, U.S. Pat. Nos.
  • MCL-1 inhibitors include, but are not limited to, AMG-176, MIK665, and S63845.
  • the myeloid cell leukemia-1 (MCL-1) protein is one of the key anti-apoptotic members of the B- cell lymphoma-2 (BCL-2) protein family.
  • BCL-1 B- cell lymphoma-2
  • Over-expression of MCL-1 has been closely related to tumor progression as well as to resistance, not only to traditional chemotherapies but also to targeted therapeutics including BCL-2 inhibitors such as ABT-263.
  • SHP inhibitors include, but are not limited to, SHP099.
  • Proteasome inhibitors include, but are not limited to, Kyprolis® (carfilzomib), Velcade® (bortezomib), and oprozomib.
  • Immune therapies include, but are not limited to, anti-PD-1 agents, anti-PDL-1 agents, anti-CTLA-4 agents, anti-LAGl agents, and anti-OX40 agents.
  • Monoclonal antibodies include, but are not limited to, Darzalex® (daratumumab), Herceptin® (trastuzumab), Avastin® (bevacizumab), Rituxan® (rituximab), and Lucentis® (ranibizumab).
  • Fusion proteins include, but are not limited to, Eylea® (aflibercept).
  • Immunomodulatory agents are a class of immunomodulatory drugs (drugs that adjust immune responses) containing an imide group.
  • the IMiD class includes thalidomide and its analogues (lenalidomide, pomalidomide, and apremilast).
  • WO 2006/121168 Al each of which are expressly incorporated by reference herein, include: YervoyTM (ipilimumab) or Tremelimumab (to CTLA-4), galiximab (to B7.1), BMS-936558 (to PD-1), MK-3475 (to PD-1), AMP224 (to B7DC), BMS-936559 (to B7-H1), MPDL3280A (to B7-H1), MEDI-570 (to ICOS), AMG557 (to B7H2), MGA271 (to B7H3), IMP321 (to LAG- 3), BMS-663513 (to CD137), PF-05082566 (to CD137), CDX-1127 (to CD27), anti-OX40 (Providence Health Services), huMAbOX40L (to OX40L), Atacicept (to TACI), CP-870893 (to CD40), Lucatumumab (to CD40), Dacetu
  • the one or more additional therapeutic agents comprise an anti- PD-1 antibody.
  • the anti-PD-1 antibody (or antigen binding antibody fragment thereof) comprises (a) the heavy chain variable region (VH) amino acid sequence in SEQ ID NO: 8, or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity, or (b) the light chain variable region (VL) amino acid sequence in SEQ ID NO: 9 or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity.
  • the anti-PD-1 antibody (or antigen binding antibody fragment thereof) comprises the heavy chain variable region amino acid sequence in SEQ ID NO: 8 and the light chain variable region amino acid sequence in SEQ ID NO: 9.
  • the anti-PD-1 antibody (or antigen binding antibody fragment thereof) comprises (a) the heavy chain (HC) amino acid sequence of SEQ ID NO: 10 or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity; or (b) the light chain (LC) amino acid sequence of SEQ ID NO: 11 or a variant sequence thereof which differs by only one or two amino acids or which has at least or about 70% sequence identity.
  • the anti-PD-1 antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 10 and the light chain amino acid sequence of SEQ ID NO: 11.
  • the antibody comprises 1, 2, 3, 4, 5, or all 6 CDRs encoded by the nucleic acid(s) of SEQ ID NOs: 12-17 (representing HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3, in that order). In some embodiments, the antibody comprises all 6 CDRs encoded by the nucleic acids of SEQ ID NOs: 12-17.
  • the anti-PD-1 antibody (or an antigen binding portion thereof) comprises (a) a heavy chain variable region encoded by SEQ ID NO: 18 or a variant sequence thereof which differs by only 1, 2, 3, 4, 5, or 6 nucleic acids or which has at least or about 70%, 85%, 90%, or 95% sequence identity, or (b) a light chain variable region encoded by SEQ ID NO: 19 or a variant sequence thereof which differs by only 1, 2, 3, 4, 5, or 6 nucleic acids or which has at least or about 70%, 85%, 90%, or 95% sequence identity.
  • the anti-PD-1 antibody (or an antigen binding portion thereof) comprises a heavy chain variable region encoded by SEQ ID NO: 18 and a light chain variable region encoded by SEQ ID NO: 19.
  • the anti-PD-1 antibody (or an antigen binding portion thereof) comprises (a) a heavy chain encoded by SEQ ID NO: 20 or a variant sequence thereof which differs by only 1, 2, 3, 4, 5, or 6 nucleic acids or which has at least or about 70%, 85%, 90%, or 95% sequence identity, or (b) a light chain encoded by SEQ ID NO: 21 or a variant sequence thereof which differs by only 1, 2, 3, 4, 5, or 6 nucleic acids or which has at least or about 70%, 85%, 90%, or 95% sequence identity.
  • the anti-PD-1 antibody (or an antigen binding portion thereof) comprises a heavy chain encoded by SEQ ID NO: 20 and a light chain encoded by SEQ ID NO: 21.
  • GITR agonists include, but are not limited to, GITR fusion proteins and anti-GITR antibodies (e.g., bivalent anti-GITR antibodies), such as, a GITR fusion protein described in U.S. Pat. No. 6,111,090 box.c, European Patent No.: 090505B1, U.S. Pat. No. 8,586,023, PCT Publication Nos.: WO 2010/003118 and 2011/090754, or an anti-GITR antibody described, e.g., in U.S. Pat. No. 7,025,962, European Patent No.: 1947183B1, U.S. Pat. Nos.
  • anti-GITR antibodies e.g., bivalent anti-GITR antibodies
  • the present disclosure provides a compound of Formula (0): an isomer thereof, or a pharmaceutically acceptable salt thereof, wherein:
  • X is CR x or N
  • R x is H, halogen, cyano, oxo, OH, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or Ci-Ce alkoxy, wherein the Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or Ci-Ce alkoxy is optionally substituted with one or more halogen, cyano, oxo, or OH;
  • R W1 is H, halogen, Ci-Ce alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
  • W 2 is N or CR W2 ;
  • W 3 is N or CR W3 ;
  • R W3 is H, halogen, Ci-Ce alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
  • W 4 is N or CR W4 ;
  • R 2 is H, halogen, cyano, oxo, OH, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or Ci-Ce alkoxy;
  • R 3 is H, halogen, cyano, oxo, OH, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or Ci-Ce alkoxy; or
  • the present disclosure provides a compound of Formula (I): an isomer thereof, or a pharmaceutically acceptable salt thereof.
  • the present disclosure provides a compound of Formula (IF): an isomer thereof, or a pharmaceutically acceptable salt thereof.
  • X is CR X or N. In some embodiments, X is N. In some embodiments, X is CR X . In some embodiments, X is CH. In some embodiments, X is C(CN). In some embodiments, X is CF.
  • R x is H, halogen, cyano, oxo, OH, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or Ci-Ce alkoxy, wherein the Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or Ci- Ce alkoxy is optionally substituted with one or more halogen, cyano, oxo, or OH.
  • R x is H, halogen, cyano, oxo, or OH.
  • R x is H.
  • R x is halogen.
  • R x is Ci-Ce alkoxy, optionally substituted with one or more OH. In some embodiments, R x is Ci alkoxy, optionally substituted with one or more OH. In some embodiments, R x is C2 alkoxy, optionally substituted with one or more OH. In some embodiments, R x is C3 alkoxy, optionally substituted with one or more OH. In some embodiments, R x is C4 alkoxy, optionally substituted with one or more OH. In some embodiments, R x is C5 alkoxy, optionally substituted with one or more OH. In some embodiments, R x is Ce alkoxy, optionally substituted with one or more OH.
  • R W3 is Ci alkyl. In some embodiments, R W3 is C2 alkyl. In some embodiments, R W3 is C3 alkyl. In some embodiments, R W3 is C4 alkyl. In some embodiments, R W3 is C5 alkyl. In some embodiments, R W3 is Ce alkyl. [0403] In some embodiments, W 4 is N or CR W4 . In some embodiments, W 4 is N. In some embodiments, W 4 is CR W4 . In some embodiments, W 4 is CH.
  • R 1 is H. In some embodiments, R 1 is Ci-Ce alkyl, wherein the Ci-Ce alkyl is substituted with one or more R la . In some embodiments, R 1 is Ci-Ce alkyl. In some embodiments, R 1 is Ci alkyl. In some embodiments, R 1 is C2 alkyl. In some embodiments, R 1 is C3 alkyl. In some embodiments, R 1 is C4 alkyl. In some embodiments, R 1 is C5 alkyl. In some embodiments, R 1 is Ce alkyl. In some embodiments, R 1 is CH3. In some embodiments, R 1 is CH2CH3.
  • R 2 is H, cyano, oxo, OH, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or Ci-Ce alkoxy.
  • R 2 is H, cyano, oxo, or OH.
  • R 2 is H.
  • R 2 is cyano.
  • R 2 is OH.
  • R 2 is Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl or Ci-Ce alkoxy.
  • R 2 is H, halogen, cyano, oxo, OH, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or Ci-Ce alkoxy.
  • R X1 is Ci-Ce alkyl, C 2 -Ce alkenyl, C 2 -Ce alkynyl, Ci-Ce alkoxy, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, Ce-Cio aryl, or 5- to 10-membered heteroaryl.
  • R X1 is Ci-Ce alkyl.
  • R X1 is CH3.
  • A is Ci-Ce alkyl, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, Ce-Cio aryl, 5- to 10-membered heteroaryl, -(Ci-Ce alkyl)-(C3-Cs cycloalkyl), -(Ci-Ce alkyl)-(3- to 8-membered heterocycloalkyl), -(Ci-Ce alkyl)-(Ce-Cio aryl), or -(Ci-Ce alkyl)-(5- to 10-membered heteroaryl), wherein the Ci-Ce alkyl, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, Ce-Cio aryl, 5- to 10-membered heteroaryl, -(Ci-Ce alkyl)- (Cs-Cs cycloalkyl), -(C
  • A is Ci-Ce alkyl, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, Ce-Cio aryl, or 5- to 10-membered heteroaryl, wherein the Ci-Ce alkyl, C3- Cs cycloalkyl, 3- to 8-membered heterocycloalkyl, Ce-Cio aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R A .
  • A is C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, Ce-Cio aryl, or 5- to 10-membered heteroaryl, wherein the C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, Ce-Cio aryl, or 5- to 10- membered heteroaryl is optionally substituted with one or more R A .
  • A is C3-C8 cycloalkyl, or 3- to 8-membered heterocycloalkyl, wherein the C3-C8 cycloalkyl, or 3- to 8-membered heterocycloalkyl is optionally substituted with one or more R A .
  • A is Ce-Cio aryl, or 5- to 10-membered heteroaryl, wherein the Ce-Cio aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R A .
  • A is Ce-Cio aryl, optionally substituted with one or more R A .
  • A is Ce-Cio aryl.
  • A is phenyl.
  • A is phenyl optionally substituted with one or more R A .
  • A is 5- to 10-membered heteroaryl, optionally substituted with one or more R A .
  • A is 5- to 10-membered heteroaryl.
  • R A is NHR A1 . In some embodiments, R A is N(R A1 ) 2 . In some embodiments, R A is N(CH3)2. In some embodiments, R A is Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-Ce alkoxy, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, Ce-Cio aryl, or 5- to 10-membered heteroaryl, wherein the Ci-Ce alkyl, C2-
  • R A is Ci-Ce alkyl.
  • R A is Ci alkyl.
  • R A is C2 alkyl.
  • R A is C3 alkyl.
  • R A is C4 alkyl.
  • R A is C5 alkyl.
  • R A is Ce alkyl.
  • R A is Ci-Ce alkyl, optionally substituted with one or more R A1 .
  • R A is Ci alkyl, optionally substituted with one or more R A1 .
  • R A is C2 alkyl, optionally substituted with one or more R A1 .
  • R A is C3 alkyl, optionally substituted with one or more R A1 .
  • R A is C4 alkyl, optionally substituted with one or more R A1 .
  • R A is C5 alkyl, optionally substituted with one or more R A1 .
  • R A is Ce alkyl, optionally substituted with one or more R A1 .
  • R A is Ci-Ce alkyl, optionally substituted with one or more halogen. In some embodiments, R A is Ci alkyl, optionally substituted with one or more halogen. In some embodiments, R A is C3 alkyl, optionally substituted with one or more halogen. In some embodiments, R A is CH3. In some embodiments, R A is CF3.
  • R A is C(CH3)2CN. In some embodiments, R A is Ci-Ce alkoxy. In some embodiments, R A is Ci alkoxy. In some embodiments, R A is C2 alkoxy. In some embodiments, R A is C3 alkoxy. In some embodiments, R A is C4 alkoxy. In some embodiments, R A is C5 alkoxy. In some embodiments, R A is Ce alkoxy. In some embodiments, R A is Ci-Ce alkoxy, optionally substituted with one or more R A1 . In some embodiments, R A is Ci alkoxy, optionally substituted with one or more R A1 .
  • R A is C2 alkoxy, optionally substituted with one or more R A1 . In some embodiments, R A is C3 alkoxy, optionally substituted with one or more R A1 . In some embodiments, R A is C4 alkoxy, optionally substituted with one or more R A1 . In some embodiments, R A is C5 alkoxy, optionally substituted with one or more R A1 . In some embodiments, R A is Ce alkoxy, optionally substituted with one or more R A1 . In some embodiments, R A is C3-C8 cycloalkyl. In some embodiments, R A is C3 cycloalkyl. In some embodiments, R A is C4 cycloalkyl.
  • R A is C5 cycloalkyl. In some embodiments, R A is Ce cycloalkyl. In some embodiments, R A is C7 cycloalkyl. In some embodiments, R A is Cs cycloalkyl.
  • R A is C3-C8 cycloalkyl, optionally substituted with one or more R A1 .
  • R A is C3 cycloalkyl, optionally substituted with one or more R A1 .
  • R A is C4 cycloalkyl, optionally substituted with one or more R A1 .
  • R A is C5 cycloalkyl, optionally substituted with one or more R A1 .
  • R A is Ce cycloalkyl, optionally substituted with one or more R A1 .
  • R A is C7 cycloalkyl, optionally substituted with one or more R A1 .
  • R A is Cs cycloalkyl, optionally substituted with one or more R A1 .
  • R A1 is halogen.
  • R A1 is fluorine.
  • R A1 is chlorine.
  • R A1 is bromine.
  • R A1 is iodine.
  • R A1 is cyano.
  • R A1 is oxo.
  • R A1 is OH.
  • R A1 is OR A2 .
  • R A1 is NH2.
  • R A1 is C3 alkyl, optionally substituted with one or more R A2 . In some embodiments, R A1 is C4 alkyl, optionally substituted with one or more R A2 . In some embodiments, R A1 is C5 alkyl, optionally substituted with one or more R A2 . In some embodiments, R A1 is Ce alkyl, optionally substituted with one or more R A2 .
  • R A is Ci-Ce alkyl and R A1 is halogen. In some embodiments, R A is Ci alkyl and R A1 is fluorine. In some embodiments, R A is Ci-Ce alkyl and R A1 is cyano. In some embodiments, R A is Ci alkyl and R A1 is cyano.
  • the compound is Compound No. 1 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 1 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 1.
  • the compound is Compound No. 3 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 3.
  • the compound is Compound No. 4.
  • the compound is Compound No. 5 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 5 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 5.
  • the compound is Compound No. 6 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 6 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 6.
  • the compound is Compound No. 7 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 7.
  • the compound is Compound No. 8.
  • the compound is Compound No. 9 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 9.
  • the compound is Compound No. 10 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 10 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 10. [0473] In some embodiments, the compound is Compound No. 11 or a pharmaceutically acceptable salt or stereoisomer thereof. [0474] In some embodiments, the compound is Compound No. 11 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 17 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 19.
  • the compound is Compound No. 20 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 21 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 21 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 22 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 22 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 22.
  • the compound is Compound No. 23 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 23 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 23.
  • the compound is Compound No. 24 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 25 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 25 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 25.
  • the compound is Compound No. 26 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 26 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 26.
  • the compound is Compound No. 27 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 27 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 27.
  • the compound is Compound No. 29 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 29 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 29.
  • the compound is Compound No. 30 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 30 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 30.
  • the compound is Compound No. 31 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 31 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 31.
  • the compound is Compound No. 32 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 32 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 32.
  • the compound is Compound No. 33 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 33 or pharmaceutically acceptable salt thereof. [0535] In some embodiments, the compound is Compound No. 33.
  • the compound is Compound No. 34 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 34 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 34.
  • the compound is Compound No. 35 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 35.
  • the compound is Compound No. 37 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 37.
  • the compound is Compound No. 38 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 38 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 38.
  • the compound is Compound No. 39.
  • the compound is Compound No. 40 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 40 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 40.
  • the compound is Compound No. 41 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 41 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 41.
  • the compound is Compound No. 42 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 42.
  • the compound is Compound No. 44.
  • the compound is Compound No. 49 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 49 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 49.
  • the compound is Compound No. 52 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 52 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 52.
  • the compound is Compound No. 53 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 53 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 53.
  • the compound is Compound No. 55 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 55 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 55.
  • the compound is Compound No. 56 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 56.
  • the compound is Compound No. 57 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 57 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 57.
  • the compound is Compound No. 58 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 58.
  • the compound is Compound No. 59.
  • the compound is Compound No. 60.
  • the compound is Compound No. 65 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 65 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 66 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 66 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 68 or pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 75 or pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 77.
  • the compound is Compound No. 78 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 78 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 78.
  • the compound is Compound No. 79 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 79 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 79.
  • the compound is Compound No. 153 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 154 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 154.
  • the compound is Compound No. 173 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 173 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 173.
  • the compound is Compound No. 174 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 174 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 175 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 176 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 176 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 176.
  • the compound is Compound No. 191 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 191 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 191.
  • the compound is Compound No. 193 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 193 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 193.
  • the compound is Compound No. 194 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 194 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 194.
  • the compound is Compound No. 200 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 214.
  • the compound is Compound No. 226 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 226.
  • the compound is Compound No. 227 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 227 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 227.
  • the compound is Compound No. 229 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 229 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 229.
  • the compound is Compound No. 230 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 230 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 230.
  • the compound is Compound No. 231 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 231 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 231.
  • the compound is Compound No. 233 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 234 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 234 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 235.
  • the compound is Compound No. 236 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 236 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 236.
  • the compound is Compound No. 237 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 238 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 238.
  • the compound is Compound No. 242 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 242 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 242.
  • the compound is Compound No. 243 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 243 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 243.
  • the compound is Compound No. 245 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 245 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 245.
  • the compound is Compound No. 247 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 247 or a pharmaceutically acceptable salt thereof. [0739] In some embodiments, the compound is Compound No. 247.
  • the compound is Compound No. 248 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 248.
  • the compound is Compound No. 249 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 255 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 255 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 255.
  • the compound is Compound No. 256 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 256.
  • the compound is Compound No. 257 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 257 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 257.
  • the compound is Compound No. 258 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 258.
  • the compound is Compound No. 259 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 259.
  • the compound is Compound No. 260 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 260 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 260.
  • the compound is Compound No. 261 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 261 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 261.
  • the compound is Compound No. 262 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 262 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 262.
  • the compound is Compound No. 263 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 263 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 263.
  • the compound is Compound No. 264 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 264 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 264.
  • the compound is Compound No. 265 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 265 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 265.
  • the compound is Compound No. 266 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 266 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 266.
  • the compound is Compound No. 267 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 267 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 267.
  • the compound is Compound No. 271 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 271 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 271.
  • the compound is Compound No. 272 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 272 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 272.
  • the compound is Compound No. 274 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 274 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 274.
  • the compound is Compound No. 275 or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is Compound No. 275 or a pharmaceutically acceptable salt thereof.
  • the compound is Compound No. 275.
  • a suitable pharmaceutically acceptable salt of a compound of the disclosure is, for example, an acid-addition salt of a compound of the disclosure which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulfuric, phosphoric, trifluoroacetic, formic, citric methane sulfonate or maleic acid.
  • an inorganic or organic acid for example hydrochloric, hydrobromic, sulfuric, phosphoric, trifluoroacetic, formic, citric methane sulfonate or maleic acid.
  • a suitable pharmaceutically acceptable salt of a compound of the disclosure which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a pharmaceutically acceptable cation, for example a salt with methylamine, dimethylamine, diethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
  • an alkali metal salt for example a sodium or potassium salt
  • an alkaline earth metal salt for example a calcium or magnesium salt
  • an ammonium salt or a salt with an organic base which affords a pharmaceutically acceptable cation, for example a salt with methylamine, dimethylamine, diethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
  • the term “isomerism” means compounds that have identical molecular formulae but differ in the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereoisomers,” and stereoisomers that are non-superimposable mirror images of each other are termed “enantiomers” or sometimes optical isomers.
  • racemic mixture A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a “racemic mixture.”
  • chiral center refers to a carbon atom bonded to four nonidentical substituents.
  • chiral isomer means a compound with at least one chiral center.
  • Compounds with more than one chiral center may exist either as an individual diastereomer or as a mixture of diastereomers, termed “diastereomeric mixture.”
  • a stereoisomer may be characterized by the absolute configuration (R or S) of that chiral center.
  • Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center.
  • the substituents attached to the chiral center under consideration are ranked in accordance with the Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al., Angew. Chem. Inter. Edit.
  • geometric isomer means the diastereomers that owe their existence to hindered rotation about double bonds or a cycloalkyl linker (e.g., 1,3-cyclobutyl). These configurations are differentiated in their names by the prefixes cis and trans, or Z and E, which indicate that the groups are on the same or opposite side of the double bond in the molecule according to the Cahn-Ingold-Prelog rules.
  • Ring-chain tautomerism arises as a result of the aldehyde group (-CHO) in a sugar chain molecule reacting with one of the hydroxy groups (-OH) in the same molecule to give it a cyclic (ring-shaped) form as exhibited by glucose.
  • An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarised light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively).
  • a chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”.
  • present disclosure encompasses all optical, diastereoisomers and geometric isomers and mixtures thereof that possess anti-tumor activity. [0821] The present disclosure also encompasses compounds of the disclosure as defined herein which comprise one or more isotopic substitutions.
  • Suitable anions include chloride, bromide, iodide, sulfate, bi sulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate, and acetate (e.g., trifluoroacetate).
  • the term “pharmaceutically acceptable anion” refers to an anion suitable for forming a pharmaceutically acceptable salt.
  • a salt can also be formed between a cation and a negatively charged group (e.g., carboxylate) on a substituted compound disclosed herein.
  • Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion or diethylamine ion.
  • the substituted compounds disclosed herein also include those salts containing quaternary nitrogen atoms.
  • the compounds of the present disclosure can exist in either hydrated or unhydrated (the anhydrous) form or as solvates with other solvent molecules.
  • Nonlimiting examples of hydrates include monohydrates, dihydrates, etc.
  • Nonlimiting examples of solvates include ethanol solvates, acetone solvates, etc.
  • solvate means solvent addition forms that contain either stoichiometric or non-stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate; and if the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one molecule of the substance in which the water retains its molecular state as H2O.
  • analog refers to a chemical compound that is structurally similar to another but differs slightly in composition (as in the replacement of one atom by an atom of a different element or in the presence of a particular functional group, or the replacement of one functional group by another functional group).
  • an analog is a compound that is similar or comparable in function and appearance, but not in structure or origin to the reference compound.
  • derivative refers to compounds that have a common core structure and are substituted with various groups as described herein.
  • bioisostere refers to a compound resulting from the exchange of an atom or of a group of atoms with another, broadly similar, atom or group of atoms.
  • the objective of a bioisosteric replacement is to create a new compound with similar biological properties to the parent compound.
  • the bioisosteric replacement may be physicochemically or topologically based.
  • Examples of carboxylic acid bioisosteres include, but are not limited to, acyl sulfonamides, tetrazoles, sulfonates and phosphonates. See, e.g., Patani and LaVoie, (Rem. Rev. 96, 3147-3176, 1996.
  • solvated forms such as, for example, hydrated forms.
  • a suitable pharmaceutically acceptable solvate is, for example, a hydrate such as hemi-hydrate, a monohydrate, a di-hydrate or a tri-hydrate. It is to be understood that the disclosure encompasses all such solvated forms that possess anti-tumor activity.
  • N- oxides Compounds of the present disclosure containing an amine function may also form N- oxides.
  • a reference herein to a compound disclosed herein that contains an amine function also includes the N-oxide.
  • one or more than one nitrogen atom may be oxidised to form an N-oxide.
  • Particular examples of N-oxides are the N-oxides of a tertiary amine or a nitrogen atom of a nitrogen-containing heterocycle.
  • N- oxides can be formed by treatment of the corresponding amine with an oxidising agent such as hydrogen peroxide or a peracid (e.g. a peroxycarboxylic acid), see for example Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages.
  • N-oxides can be made by the procedure of L. W. Deady (Syn. Comm. 1977, 7, 509-514) in which the amine compound is reacted with meta-chloroperoxybenzoic acid (mCPBA), for example, in an inert solvent such as dichloromethane.
  • mCPBA meta-chloroperoxybenzoic acid
  • the compounds of the present disclosure may be administered in the form of a prodrug which is broken down in the human or animal body to release a compound of the disclosure.
  • a prodrug may be used to alter the physical properties and/or the pharmacokinetic properties of a compound of the disclosure.
  • a prodrug can be formed when the compound of the disclosure contains a suitable group or substituent to which a property-modifying group can be attached.
  • Examples of prodrugs include derivatives containing in vivo cleavable alkyl or acyl substituents at the sulfonylurea group in a compound of the any one of the Formulae disclosed herein.
  • the present disclosure includes those compounds of the present disclosure as defined hereinbefore when made available by organic synthesis and when made available within the human or animal body by way of cleavage of a prodrug thereof. Accordingly, the present disclosure includes those compounds of the present disclosure that are produced by organic synthetic means and also such compounds that are produced in the human or animal body by way of metabolism of a precursor compound, that is a compound of the present disclosure may be a synthetically-produced compound or a metabolically-produced compound.
  • a suitable pharmaceutically acceptable prodrug of a compound of the present disclosure is one that is based on reasonable medical judgment as being suitable for administration to the human or animal body without undesirable pharmacological activities and without undue toxicity.
  • prodrug Various forms of prodrug have been described, for example in the following documents: a) Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985); c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 “Design and Application of Pro-drugs”, by H. Bundgaard p. 113-191 (1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H.
  • a suitable pharmaceutically acceptable prodrug of a compound of the present disclosure that possesses a hydroxy group is, for example, an in vivo cleavable ester or ether thereof.
  • An in vivo cleavable ester or ether of a compound of the present disclosure containing a hydroxy group is, for example, a pharmaceutically acceptable ester or ether which is cleaved in the human or animal body to produce the parent hydroxy compound.
  • Suitable pharmaceutically acceptable ester forming groups for a hydroxy group include inorganic esters such as phosphate esters (including phosphoramidic cyclic esters).
  • ester forming groups for a hydroxy group include Ci-Cio alkanoyl groups such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups, Ci-Cio alkoxycarbonyl groups such as ethoxycarbonyl, N,N-(Ci-Ce alkyl)2carbamoyl, 2- dialkylaminoacetyl and 2-carboxyacetyl groups.
  • Suitable pharmaceutically acceptable ether forming groups for a hydroxy group include a-acyloxyalkyl groups such as acetoxymethyl and pivaloyloxymethyl groups.
  • a suitable pharmaceutically acceptable prodrug of a compound of the present disclosure that possesses a carboxy group is, for example, an in vivo cleavable amide thereof, for example an amide formed with an amine such as ammonia, a Ci-4alkylamine such as methylamine, a (C1-C4 alkyl)2amine such as dimethylamine, N-ethyl-N-methylamine or diethylamine, a C1-C4 alkoxy-C2-C4 alkylamine such as 2-methoxy ethylamine, a phenyl-Ci-C4 alkylamine such as benzylamine and amino acids such as glycine or an ester thereof.
  • an amine such as ammonia
  • a Ci-4alkylamine such as methylamine
  • a (C1-C4 alkyl)2amine such as dimethylamine, N-ethyl-N-methylamine or diethylamine
  • a suitable pharmaceutically acceptable prodrug of a compound of the present disclosure that possesses an amino group is, for example, an in vivo cleavable amide derivative thereof.
  • Suitable pharmaceutically acceptable amides from an amino group include, for example an amide formed with C1-C10 alkanoyl groups such as an acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups.
  • ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N- dialkylaminomethyl, morpholinomethyl, piperazin- 1-ylmethyl, and 4-(CI-C4 alkyl)piperazin- 1-ylmethyl.
  • the in vivo effects of a compound of the present disclosure may be exerted in part by one or more metabolites that are formed within the human or animal body after administration of a compound of the present disclosure. As stated hereinbefore, the in vivo effects of a compound of the present disclosure may also be exerted by way of metabolism of a precursor compound (a prodrug).
  • the present disclosure provides a method of preparing a compound, comprising one or more steps as described herein.
  • the present disclosure provides a compound obtainable by, or obtained by, or directly obtained by a method for preparing a compound described herein.
  • the present disclosure provides an intermediate being suitable for use in a method for preparing a compound described herein.
  • the compounds of the present disclosure can be prepared by any suitable technique known in the art. Particular processes for the preparation of these compounds are described further in the accompanying examples.
  • a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl, or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl.
  • the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed by, for example, hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an acyl group such as a tert-butoxy carbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulfuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium on carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
  • a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
  • a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl.
  • the deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium, sodium hydroxide or ammonia.
  • a suitable base such as an alkali metal hydroxide, for example lithium, sodium hydroxide or ammonia.
  • an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium on carbon.
  • a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a tert-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium on carbon.
  • a base such as sodium hydroxide
  • a tert-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium on carbon.
  • the processes may then further comprise the additional steps of: (i) removing any protecting groups present; (ii) converting the compound of the present disclosure into another compound of the present disclosure; (iii) forming a pharmaceutically acceptable salt, hydrate or solvate thereof; and/or (iv) forming a prodrug thereof.
  • the reaction of the compounds is carried out in the presence of a suitable solvent, which is preferably inert under the respective reaction conditions.
  • suitable solvents comprise but are not limited to hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as tri chlorethylene, 1,2- di chloroethane, tetrachloromethane, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF), 2-methyltetrahydrofuran, cyclopentylmethyl ether (CPME), methyl tert-butyl ether (MTBE) or dioxane; glycol ethers, such as
  • the reaction temperature is suitably between about -100 °C and 300 °C, depending on the reaction step and the conditions used.
  • Reaction times are generally in the range between a fraction of a minute and several days, depending on the reactivity of the respective compounds and the respective reaction conditions. Suitable reaction times are readily determinable by methods known in the art, for example reaction monitoring. Based on the reaction temperatures given above, suitable reaction times generally lie in the range between 10 minutes and 48 hours.
  • Compounds designed, selected and/or optimized by methods described above, once produced, can be characterized using a variety of assays known to those skilled in the art to determine whether the compounds have biological activity.
  • the molecules can be characterized by conventional assays, including but not limited to those assays described below, to determine whether they have a predicted activity, binding activity and/or binding specificity.
  • high-throughput screening can be used to speed up analysis using such assays. As a result, it can be possible to rapidly screen the molecules described herein for activity, using techniques known in the art. General methodologies for performing high- throughput screening are described, for example, in Devlin (1998) High Throughput Screening, Marcel Dekker; and U.S. Patent No. 5,763,263. High-throughput assays can use one or more different assay techniques including, but not limited to, those described below.
  • the biological assay may involve retroviral production.
  • cells e.g., BaF3 BRAF -KIAA1549 fusion cells
  • cells are suspended and dispensed in plates.
  • the cells e.g., BaF3 BRAF -KIAA1549 fusion cells
  • the cells may be incubated in the presence of vehicle control (e.g., DMSO) or a compound of the present disclosure at varying concentrations and the inhibition of cell growth may be determined by luminescent quantification (e.g., of intracellular ATP content using CellTiterGlo), according to the manufacturers protocol.
  • vehicle control e.g., DMSO
  • luminescent quantification e.g., of intracellular ATP content using CellTiterGlo
  • the vehicle- treated cells were normalized as viable cells and analyzed using a software (e.g., the CDD Vault (Collaborative Drug Discovery, Burlingame, CA) using an algorithm (e.g., the Levenberg-Marquardt algorithm; Levenberg, K., 1994; Marquardt, D., 1963).
  • a software e.g., the CDD Vault (Collaborative Drug Discovery, Burlingame, CA) using an algorithm (e.g., the Levenberg-Marquardt algorithm; Levenberg, K., 1994; Marquardt, D., 1963).
  • compositions of the disclosure may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art.
  • compositions intended for oral use may contain, for example, one or more coloring, sweetening, flavoring and/or preservative agents.
  • the size of the dose for therapeutic or prophylactic purposes of a compound of the present disclosure will naturally vary according to the nature and severity of the conditions, the age and sex of the animal, subject, or patient and the route of administration, according to well- known principles of medicine.
  • X is CR x or N
  • R x is H, halogen, cyano, oxo, OH, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or Ci-Ce alkoxy, wherein the Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or Ci-Ce alkoxy is optionally substituted with one or more halogen, cyano, oxo, or OH;
  • W 1 is N or CR W1 ;
  • R W1 is H, halogen, Ci-Ce alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
  • W 2 is N or CR W2 ;

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des méthodes de traitement ou de prévention du cancer à l'aide d'un composé de formule (0) : ou d'un sel pharmaceutiquement acceptable de celui-ci. La présente invention concerne également des compositions pharmaceutiques et des kits pharmaceutiques appropriés pour le traitement ou la prévention.
EP23805790.5A 2022-10-14 2023-10-13 Méthodes de traitement de cancers à l'aide de dérivés d'isoquinoline ou de 6-aza-quinoléine Pending EP4601644A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263416305P 2022-10-14 2022-10-14
US202263431997P 2022-12-12 2022-12-12
US202363449757P 2023-03-03 2023-03-03
US202363472037P 2023-06-09 2023-06-09
PCT/US2023/076892 WO2024081916A1 (fr) 2022-10-14 2023-10-13 Méthodes de traitement de cancers à l'aide de dérivés d'isoquinoline ou de 6-aza-quinoléine

Publications (1)

Publication Number Publication Date
EP4601644A1 true EP4601644A1 (fr) 2025-08-20

Family

ID=88793147

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23805790.5A Pending EP4601644A1 (fr) 2022-10-14 2023-10-13 Méthodes de traitement de cancers à l'aide de dérivés d'isoquinoline ou de 6-aza-quinoléine

Country Status (15)

Country Link
EP (1) EP4601644A1 (fr)
JP (1) JP2025536257A (fr)
KR (1) KR20250102034A (fr)
CN (1) CN120359029A (fr)
AU (1) AU2023358792A1 (fr)
CL (1) CL2025001119A1 (fr)
CO (1) CO2025004701A2 (fr)
CR (1) CR20250141A (fr)
DO (1) DOP2025000090A (fr)
GE (1) GEAP202516749A (fr)
IL (1) IL320217A (fr)
JO (1) JOP20250076A1 (fr)
MX (1) MX2025004409A (fr)
PE (1) PE20251879A1 (fr)
WO (1) WO2024081916A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202606668A (zh) * 2024-04-24 2026-02-16 美商黑鑽醫療公司 ６－吖喹啉衍生物之晶型及鹽類以及相關用途
WO2026039338A1 (fr) * 2024-08-12 2026-02-19 Black Diamond Therapeutics, Inc. Compositions comprenant des dérivés de quinazoline substitués par alcyne et utilisations associées

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3381783D1 (de) 1982-03-03 1990-09-13 Genentech Inc Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
CA2102780C (fr) 1991-05-10 2007-01-09 Alfred P. Spada Composes de type bis-monoaryle, aryle bicyclique et (ou) heteroaryle inhibant l'activite de tyrosine kinase des recepteurs de l'egf et (ou) du pdgf
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
PT669929E (pt) 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
JPH08503971A (ja) 1993-10-01 1996-04-30 チバ−ガイギー アクチェンゲゼルシャフト ピリミジンアミン誘導体及びその調製のための方法
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
WO1995014023A1 (fr) 1993-11-19 1995-05-26 Abbott Laboratories Analogues semi-synthetiques de rapamycine (macrolides) utilises comme immunomodulateurs
PT734389E (pt) 1993-12-17 2000-09-29 Novartis Ag Derivados de rapamicina uteis como imunossupressores
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
WO1995024190A2 (fr) 1994-03-07 1995-09-14 Sugen, Inc. Inhibiteurs de tyrosine-kinase receptrice destines a inhiber les troubles lies a la proliferation cellulaire et compositions les contenant
AU702522B2 (en) 1994-04-15 1999-02-25 Amgen, Inc. HEK5, HEK7, HEK8, HEK11, new EPH-like receptor protein tyrosine kinases
DE59500788D1 (de) 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
JP4249804B2 (ja) 1995-04-03 2009-04-08 ノバルティス・アクチエンゲゼルシャフト ピラゾール誘導体およびその製造法
JP3053222B2 (ja) 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5650415A (en) 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
CZ292233B6 (cs) 1995-06-09 2003-08-13 Novartis Ag Deriváty rapamycinu a jejich použití jako léčiv
EP0836605B1 (fr) 1995-07-06 2002-02-06 Novartis AG Pyrrolopyrimidines et leurs procedes de preparation
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
AU1441497A (en) 1996-01-23 1997-08-20 Novartis Ag Pyrrolopyrimidines and processes for their preparation
JP3406763B2 (ja) 1996-01-30 2003-05-12 東レ・ダウコーニング・シリコーン株式会社 シリコーンゴム組成物
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
DE19629652A1 (de) 1996-03-06 1998-01-29 Thomae Gmbh Dr K 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19608588A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6051577A (en) 1996-03-15 2000-04-18 Novartis Ag N-7-heterocyclyl pyrrolo[2,3-D]pyrimidines and the use thereof
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
EP0907642B1 (fr) 1996-06-24 2005-11-02 Pfizer Inc. Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives
EP0818442A3 (fr) 1996-07-12 1998-12-30 Pfizer Inc. Dérivés cycliques de sulfones comme inhibiteurs de métalloprotéinase et de la production du facteur de nécrose des tumeurs
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
DE69716916T2 (de) 1996-07-13 2003-07-03 Glaxo Group Ltd., Greenford Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EA199900021A1 (ru) 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
CA2260898C (fr) 1996-07-18 2002-05-14 Pfizer Limited Composes a base de phosphinate inhibiteurs des metalloproteases matricielles
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
DE69738749D1 (de) 1996-08-16 2008-07-17 Schering Corp Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
PL331895A1 (en) 1996-08-23 1999-08-16 Pfizer Arylosulphonylamino derivatives of hydroxamic acid
AU720429B2 (en) 1996-08-23 2000-06-01 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
ES2239779T3 (es) 1996-10-02 2005-10-01 Novartis Ag Derivados de pirimidina y procedimientos para la preparacion de los mismos.
AU4779897A (en) 1996-10-02 1998-04-24 Novartis Ag Fused pyrazole derivatives and processes for their preparation
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
EP0837063A1 (fr) 1996-10-17 1998-04-22 Pfizer Inc. Dérivés de 4-aminoquinazoline
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
DE69730151T2 (de) 1997-01-06 2005-08-04 Pfizer Inc. Cyclische sulfonderivate
AU721748B2 (en) 1997-02-03 2000-07-13 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
KR20000070751A (ko) 1997-02-05 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
CA2279863A1 (fr) 1997-02-07 1998-08-13 Pfizer Inc. Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices
WO1998034918A1 (fr) 1997-02-11 1998-08-13 Pfizer Inc. Derives de l'acide arylsulfonylhydroxamique
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6150395A (en) 1997-05-30 2000-11-21 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
WO1999007701A1 (fr) 1997-08-05 1999-02-18 Sugen, Inc. Derives de quinoxaline tricyclique utiles en tant qu'inhibiteurs de proteine tyrosine kinase
ID23668A (id) 1997-08-08 2000-05-11 Pfizer Prod Inc Turunan asam ariloksiarilsulfonilamino hidroksamat
WO1999020758A1 (fr) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Proteines tr11, tr11sv1 et tr11sv2 de type recepteur du facteur de necrose tumorale humain
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
JP2002502607A (ja) 1998-02-09 2002-01-29 ジェネンテク・インコーポレイテッド 新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸
ES2324846T3 (es) 1998-03-04 2009-08-17 Bristol-Myers Squibb Company Inhibidores de la proteina tirosina quinasa de imidazopirazina heterociclo-sustituida.
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
IL139934A0 (en) 1998-05-29 2002-02-10 Sugen Inc Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
CA2336848A1 (fr) 1998-07-10 2000-01-20 Merck & Co., Inc. Nouveaux inhibiteurs de l'angiogenese
EP1109555A4 (fr) 1998-08-31 2001-11-21 Merck & Co Inc Nouveaux inhibiteurs d'angiogenese
DK1004578T3 (da) 1998-11-05 2004-06-28 Pfizer Prod Inc 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
CA2359244C (fr) 1999-01-13 2013-10-08 Bayer Healthcare Llc Diphenyle urees a substitution .omega.-carboxy aryle en tant qu'inhibiteurs de la kinase p38
JP4673977B2 (ja) 1999-03-30 2011-04-20 ノバルティス アーゲー 炎症性疾患治療用フタラジン誘導体
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
ATE324444T1 (de) 1999-06-07 2006-05-15 Immunex Corp Tek-antagonisten
PT1196186E (pt) 1999-07-12 2008-02-14 Genentech Inc Promoção ou inibição da angiogénese e da cardiovascularização com homólogos de ligandos/receptores do factor de necrose tumoral.
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
CN100376567C (zh) 1999-11-05 2008-03-26 阿斯特拉曾尼卡有限公司 作为vegf抑制剂的喹唑啉衍生物
DK1233943T3 (da) 1999-11-24 2011-08-15 Sugen Inc Ioniserbare indolinon derivater og anvendelse deraf som PTK ligander
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
EP1259595B1 (fr) 2000-02-25 2007-04-04 Immunex Corporation Antagonistes des integrines
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
ES2556946T3 (es) 2000-12-21 2016-01-21 Novartis Ag Pirimidinaminas como moduladores de la angiogénesis
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2004244626A1 (en) 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
WO2005005434A1 (fr) 2003-07-08 2005-01-20 Novartis Ag Utilisation de rapamycine et de derives de rapamycine pour traiter les pertes de masse osseuse
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
EP1648900A4 (fr) 2003-07-11 2010-02-10 Ariad Pharma Inc Macrocycles contenant du phosphore
AR045134A1 (es) 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
WO2005055808A2 (fr) 2003-12-02 2005-06-23 Genzyme Corporation Compositions et methodes pour le diagnostic et le traitement du cancer du poumon
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
US20060002932A1 (en) 2004-06-04 2006-01-05 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
GEP20104906B (en) 2004-08-26 2010-02-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CN101039952A (zh) 2004-10-13 2007-09-19 惠氏公司 作为pi3k抑制剂的17－羟基渥曼青霉素类似物
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2622870A1 (fr) 2005-09-20 2007-03-29 Pfizer Products Inc. Formes de dosage et procedes de traitement utilisant un inhibiteur de la tyrosine kinase
WO2007133822A1 (fr) 2006-01-19 2007-11-22 Genzyme Corporation Anticorps anti-gitr destinés au traitement du cancer
WO2008070740A1 (fr) 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Composés inhibant la phosphoinositide 3 kinase et procédés d'utilisation
CN101801413A (zh) 2007-07-12 2010-08-11 托勒克斯股份有限公司 采用gitr结合分子的联合疗法
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
EP2214675B1 (fr) 2007-10-25 2013-11-20 Genentech, Inc. Procédé de préparation de composés de thiénopyrimidine
US20100197688A1 (en) * 2008-05-29 2010-08-05 Nantermet Philippe G Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
KR20110044992A (ko) 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＧＦ-β 길항제 다중-표적 결합 단백질
CN102149820B (zh) 2008-09-12 2014-07-23 国立大学法人三重大学 能够表达外源gitr配体的细胞
PT3023438T (pt) 2009-09-03 2020-05-08 Merck Sharp & Dohme Anticorpos anti-gitr
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
TW201307292A (zh) * 2010-12-17 2013-02-16 Hoffmann La Roche 經取代之６，６－稠合含氮雜環化合物及其用途
WO2013039954A1 (fr) 2011-09-14 2013-03-21 Sanofi Anticorps anti-gitr
US9187474B2 (en) * 2012-03-07 2015-11-17 Deciphera Pharmaceuticals, Llc Raf inhibitor compounds
JP2023549540A (ja) * 2020-11-18 2023-11-27 デシフェラ・ファーマシューティカルズ，エルエルシー Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法
US20250017914A1 (en) * 2021-09-10 2025-01-16 Black Diamond Therapeutics, Inc. 6-aza-quinoline derivatives and related uses

Also Published As

Publication number Publication date
CL2025001119A1 (es) 2025-07-11
JOP20250076A1 (ar) 2025-04-13
GEAP202516749A (en) 2025-07-25
KR20250102034A (ko) 2025-07-04
PE20251879A1 (es) 2025-07-22
AU2023358792A1 (en) 2025-04-17
CO2025004701A2 (es) 2025-05-08
JP2025536257A (ja) 2025-11-05
CN120359029A (zh) 2025-07-22
IL320217A (en) 2025-06-01
DOP2025000090A (es) 2025-07-31
MX2025004409A (es) 2025-05-02
WO2024081916A1 (fr) 2024-04-18
CR20250141A (es) 2025-05-26

Similar Documents

Publication Publication Date Title
AU2022360536B2 (en) Ras inhibitors
JP7812056B2 (ja) 二環式ヘテロアリール化合物及びその使用
US11053226B2 (en) KRAS G12C inhibitors and methods of using the same
JP7516029B2 (ja) Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7361722B2 (ja) Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法
ES2938987T3 (es) Inhibidores de KRAS G12c y métodos de uso de los mismos
US20260028339A1 (en) Synthesis of KRAS G12C Inhibitor Compound
US10640504B2 (en) Inhibitors of KRAS G12C and methods of using the same
US20240190862A1 (en) Epoxyamides as kras g12c and kras g12d inhibitors and methods of using the same
WO2023215256A1 (fr) Inhibiteurs de sos1 et leurs utilisations
EP3931195A1 (fr) Composés hétéroaryle bicycliques et leurs utilisations
WO2023215257A2 (fr) Inhibiteurs de sos1 et leurs utilisations
WO2021097212A1 (fr) Synthèse améliorée de composé inhibiteur de kras g12c
CA3203111A1 (fr) Inhibiteurs de sos1 et utilisations associees
AU2023358792A1 (en) Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
HK40128025A (zh) 使用异喹啉或6-氮杂-喹啉衍生物治疗癌症的方法
HK40055588A (en) Improved synthesis of key intermediate of kras g12c inhibitor compound

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250403

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40127849

Country of ref document: HK

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BLACK DIAMOND THERAPEUTICS, INC.